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1 INTRODUCTION 
1.1 RESEARCH, DRUG DISCOVERY AND DEVELOPMENT 
1.1.1 The productivity of the sector 
Since the human genome was sequenced ten years ago, the number of compounds in development has 
increased by 62% and total R&D expenditures have doubled1 (Figure 3). Twenty nine FDA2  approvals per 
year has been average over the past two decades for novel drugs classified as new molecular entities 
(NMEs) and biologic license applications (BLAs). Productivity per year is almost constant, after a peak in 
2012 of 38 approvals, in 20133 they decreased to 27, demonstrating that no significant improvement has 
been made since 1993 (Figure 1) 
 
Figure 1. FDA Drug Approvals 1993-2013 
The entire process to develop a new drug from the identification of a target to the registration and 
commercialization of new NMEs takes between 10 and 15 years4 (Figure 2), with one of the lowest chances 
of success compared to other industrial sectors5. This is because of the very low probability of phase 
transition in clinics where the costs are higher6 and the candidate drugs are exposed to the patients. In the 
last 10 years, the drug discovery process has been re-engineered and optimized obtaining a dramatic 
reduction in failures due to the development of poorly validated candidate drugs7.  
In 1991, the main issue for a clinical failure was drug metabolism and pharmacokinetics (DMPK),essentially, 
the physic-chemical properties of the molecules; in the year 2000, this problem was successfully addressed, 
since when the clinical safety of the candidate drugs has become the most relevant reason for a clinical 
failure7. 
Nowadays,  low efficacy is responsible for clinical failure; the success rate is about  32% in phase II and 60% 
in phase III clinical trials1. With a global probability of success of 10%1, the total cost of bringing a NCE into 
the market is 10 ten times higher than the R&D costs of the drug itself due to the 9 out of 10 failures.  
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. 
Figure 2 from Target Identification to Post Marketing (Source: Adapted from Pharmaceutical Research and Manufacturers of 
America, Drug Discovery and Development: Understanding the R&D Process, www.innovation.org.) 
1.1.1 Economics 
To maintain the same average productivity in terms of NCEs per year, global R&D costs of the pharmaceutical industry 
increased more than 4 fold from 31 US$ billion in 1990 to 140 US$ billion in 2008, whereas from 2008 to 2013 the 
spending has been almost constant with an average spending of 137 US$ billion (Figure 3)8. 
Over the last 6 years, the global R&D costs and productivity have remained stable meaning that the heavy cost 
optimization, refocusing of the research activities and massive layoffs was due to the consolidation of the transition 
from internal research to contract research rather than to a disinvestment in Pharma R&D. 
 
Figure 3. .Aggregate industry spending on research and development. All values inflation adjusted to 2013. (Sources: 
EvaluatePharma; US Food and Drug Administration (FDA); Boston Consulting Group (BCG) analysis.) 
If we do not consider the registration of new NCEs as a unique criteria of productivity, extending the 
analysis also to the other products such as:  bioengineered vaccines, combination products, enantiomers, 
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prodrugs, and therapeutic blood and plasma products, that can be collectively called new therapeutic drugs 
(NTDs)8, the overall productivity of the sector is consistent with the allocated resources in R&D. 
In fact, even if the R&D costs are estimated to be close to 2 billion for each drug reaching the market (considering the 
failures), the pharmaceutical market referring only to the top 25 pharmaceutical companies in 2013 is still in growth( > 
2%) with a global growth in sales of more than a billion over what time period (Figure 4). 
 
Figure 4. Top 25 pharma companies by global sales 2012-2013 
If compared to other industrial sectors pharmaceuticals is one of the most profitable markets (Error! 
Reference source not found.) comparable to internet companies like Google and ICT leaders such as Apple 
Inc, with a stable outlook compared other tech and media markets. 
Table 1. Profitability Analysis of key players in different industrial sectors 2014 (Source: http://www.bloomberg.com/) 
Ticker Name Return on Capital Profit Margin 
PHARMA Average 14.39 20.32 
NOVN VX Novartis AG 12.57 21.64 
SAN FP Sanofi 6.62 20.29 
ROG VX Roche Holding AG 30.78 26.33 
GSK LN GlaxoSmithKline PLC 19.72 20.45 
AZN LN AstraZeneca PLC 5.67 24.58 
PFE US Pfizer Inc 10.04 29.64 
MRK US Merck & Co Inc 8.07 23.72 
AUTOMOT Average 11.09 4.5 
TM US Toyota Motor Corp 6.73 
 7267 JP Honda Motor Co Ltd 5.6 
 7201 JP Nissan Motor Co Ltd 4.74 
 GM US General Motors Co 4.5 
 F US Ford Motor Co 
 
4.5 
RETAIL Average 12.35 1.55 
WMT US Wal-Mart Stores Inc 12.98 
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RDSA LN Royal Dutch Shell PLC 7.73 
 TECH Average 13.97 15.6 
GOOG US Google Inc 13.67 
 YHOO US Yahoo! Inc 
 
35.18 
FB US Facebook Inc 
 
27.97 
AAPL US Apple Inc 27.7 
 MSFT US Microsoft Corp 20.69 
 Manuf Average 11.89 13.83 
PG US Procter & Gamble Co/The 11.1 
 KMB US Kimberly-Clark Corp 20.47 10.56 
 
1.1.2 How it is possible to enhance the productivity (and knowledge)? 
Lack of efficacy in clinics in 68% of the phase II clinical trials highlights the biggest challenge for drug 
discovery and development9. The goal in this process is the identification of clinically validated biological 
targets with a proven disease modifying effect on patients and the development of effective translational 
models in the preclinical phase. We are, in any case still far from reaching this goal as demonstrated by the 
very low success rate in clinical development in oncology. With a probability Of being successful in clinics of 
only 7%, oncology is the therapeutic area with the lowest probability of success despite the fact that it is 
one of the most financed, “personalized”10 and stratified11 disease indication.  
To make evident the effect of the attrition rate of bringing novel and effective treatment to address the 
unmet medical needs of society, the most urgent needs in Europe in terms of healthcare are reported, as 
presented by the European Commission during the Workshop on "High Performance Computing (HPC) in 
Health Research” in Brussels, 1 - 2 October 2014: 
1. 2 million deaths in Europe due to cardiovascular diseases costing €192 billion 
2. 27 million people suffering from diabetes and 120 million with rheumatic and musculoskeletal 
conditions with large cost implications 
3. Brain disorders cost an estimated €800 billion 
4. In England treatment of Alzheimer’s disease costs approximately £17 billion 
Such data mean that we still have a poor understanding of the biological process and key mediators in 
diseases. On the other hand the R&D pharma model has to be revised in order to address the issue from a 
different perspective in fact, as demonstrated in the previous paragraph, the contract research model has 
reached the plateau of productivity. 
One possible and more fruitful solution, alternative to contacts research, is the establishment of 
collaborations with hospitals, public research institutions and academia. This approach effectively supports 
the identification and clinical validation of new targets being, at the same time, as close as possible to 
actual patients’ conditions even in the earliest discovery phases.  
Many initiatives under the buzzword “open innovation”12 have been reported so far. Here I report the one 
that is, to me, a great example of a successful implementation of the open model: the Structural Genomics 
Consortium (SGC).  
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“The SGC catalyzes research in new areas of human biology and drug discovery by focusing explicitly on less 
well-studied areas of the human genome. The SGC accelerates research in these new areas by making all its 
research output available e to the scientific community with no strings attached, and by creating an open 
collaborative network of scientists in hundreds of universities around the world and in nine global pharmaceutical 
companies. Together, this network of academic and industry scientists is driving a new scientific and drug 
discovery ecosystem whose primary aim is to advance science and is less influenced by personal, institutional or 
commercial gain. ” << http://www.thesgc.org/about/what_is_the_sgc >> 
SGC embraces the entire drug discovery and development process from the identification of novel targets 
to the clinical validation of the identified chemical probes. SGC has already been successful in both these 
activities demonstrating that radically new research models avoiding data access restriction and without 
any patent protection can bring real benefits to patients and nevertheless be valuable products for 
pharmaceutical industries. 
As said before a big issue is the poor comprehension of the key biological process related to a pathology. To 
enhance the knowledge and then the productivity of the sector, data mining, analysis and modeling and 
computer simulations could be part of the solution to the problem. In the next five years, exascale 
computing will become a reality and will bring to the research community huge data storage facilities with 
almost unlimited computing power. Starting from software as a service (SaaS) with many of them already 
available today in the terascale era, to Platforms as a Service (PaaS) and entire Virtual research 
environments (VRE) the ICT/HPC the computer could be the driving force of the change. 
 
“VREs are expected to result in more effective collaboration between researchers and higher efficiency and 
creativity in research as well as in higher productivity of researchers thanks to reliable and easy access to 
discovery, access and re-use of data. They will  accelerate innovation in research via an integrated access to 
potentially unlimited digital research resources, tools and services across disciplines and user communities 
and enable researchers to process structured and qualitative data in virtual and/or ubiquitous workspaces. 
They will contribute to increased take-up of collaborative research and data sharing by new disciplines, 
research communities and institutions.”  
“VRE should abstract from the underlying e-infrastructures using standardized building blocks and 
workflows, well documented interfaces, in particular regarding APIs, and interoperable components. Over 
time VREs will be composed of generic services delivered by e-infrastructures and domain specific services 
co-developed and co-operated by researchers, technology and e-infrastructure providers, and possibly 
commercial vendors.” 
<<http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/2144-einfra-9-
2015.html >> 
 
Therefore, exascale is not only limited to the vertical application of huge computer simulations but the 
exascale can be reached by a pervasive use of ICT and HPC architectures from the entire community of 
researchers from theoretical physics to the doctor in the hospital. 
To achieve this goal the Research and Innovation department of the European Commission has designed 
specific grants in the Horizon 2020 program from VRE to Centres of Excellence (CoE) for computing 
applications. 
Even more relevant than the infrastructure is the possibility of having access to relevant information13, such 
as Medical claims, Prescription claims, Electronic medical records (EMRs), Diagnostics, Biomarkers, 
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Admission, discharge, transfer, Drug orders and sales, Safety and Pharmaco-vigilance , Clinical research, 
Social media in combination with environmental geo referenced data such as climate, food consumption, 
pollutions, electromagnetic sources … 
The combination of ICT/HPC infrastructures with huge collections of curated data assure the acquisition of new 
knowledge by the research community although this promise will be maintained only if the software for the data 
analytics and in silico simulations are ready to take full advantage of the present and future infrastructure, but which 
is currently more of a software the bottleneck. 
1.2 Computer Aided Drug Discovery and Development  
Computer-aided14 Drug Discovery and Development (CADDD) approaches have been widely used in 
pharmaceutical research to improve the efficiency of the drug discovery and development pipeline. To 
identify and design small molecules as clinically effective therapeutics, various computational methods 
have already been evaluated as promising strategies. The original definition refers to the most established 
applications mainly in the medicinal chemistry area: 
 the conformational analysis of molecular structure: e.g., molecular dynamics 
 the characterization of drug–target interactions: e.g., molecular docking 
 the identification of most relevant features shared by a set of active ligands: pharmacophore 
analysis 
 the analysis of the chemical space and chemical library design: cheminformatics  
 the assessment and optimization of drug activity using quantitative and qualitative structure-
activity relationships: e.g.,  Q(q)SARs. 
The amount and variety of biological data now available, together with techniques developed so far have 
enabled research in Bioinformatics to move beyond the study of individual biological components (genes, 
proteins etc), albeit in a genome-wide context, to attempt to study how individual parts cooperate in their 
operation. Bioinformatics has now moved closer to the area of Systems Biology which seeks to integrate 
biological data in an attempt to understand how biological systems function. By studying the relationships 
and interactions between various parts of a biological system, it is hoped that an understandable model of 
the whole system can be developed. 
Bioinformatics and Systems Biology are now fully integrated in the drug discovery and development 
process. 
Other CADDD disciplines have an ever-increasing role in the R&D process. 
Pharmacometrics15 or Quantitative Pharmacology is defined as the science that quantifies drug, disease and 
trial information to aid efficient drug development, regulatory decisions and rational drug treatment in 
patients. Pharmacometrics uses models based on systems pharmacology, physiology and disease for 
quantitative analysis of interactions between drugs and patients. This involves pharmacokinetics, 
pharmacodynamics and disease progression with a focus on populations and variability. In the field of 
phamacometrics for example, compartmental models for predicting oral drug absorption16 including 
compartmental absorption and transit model; Grass model; the gastrointestinal transit absorption model; 
advanced compartmental absorption and transit model; and advanced dissolution, absorption, and 
metabolism model have demonstrated greatly improved predictive performance if compared with mid-
1990s QSAR models based on physic-chemical descriptors. 
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One example of the frontier of the contemporary biomedicine from a computational perspective is the 
Virtual Physiological Human Project17. The VPH is a framework of methods and technologies that once 
established will make it possible to investigate the human body as a whole. VPH is a Large-scale research 
initiative started in 2005 with > 200 million Euro and involving more than 2000 researchers in Europe. The 
final goal of the project is to allow the possibility to perform In silico clinical trials. 
In silico clinical trials will use computer simulation in the development and in the assessment of new drugs, 
new medical devices, new health technologies. In silico clinical trials will use patient-specific computer 
modelling and simulation applied in the research and development of new biomedical products, as well as 
in their evaluation and assessment, both clinical and pre-clinical. 
Therefore, the question is, in the highlighted futuristic scenario, Is there still interest in the further 
development of traditional structure-based and ligand based algorithms and tools? 
The answer is yes, and for many reasons. The most relevant ones are: 
1. Traditional molecular level computer simulations are complementary to the compartmental models. 
2. Even if well established, the algorithms (for example the scoring functions of the molecular docking 
tools) are far from being able to produce accurate ligand-receptor affinities predictions. 
3. Most of the available software is not designed for real HPC simulation so it will be not possible to 
take full advantages of the exascale architecture. 
More efficient tools in early drug discovery have demonstrated their usefulness in the reduction of the attrition rate18 
in  the preclinical phase by enriching for example the number of hits in High Throughput Screening  (HTS) Campaigns 
or in the development of robust SARs. 
The compelling need for efficient computer simulation tools enabled for HPC infrastructures is 
demonstrated by the creation worldwide only this year (2014) of 3 HPC centers devoted to molecular 
simulations. Press releases are reported: 
1. “Fujitsu Provides TC Cloud Service to the University of Tokyo's RCAST for In Silico Drug Discovery 
Research” 
2. Fujitsu HPC Competency Center  “envisages that demand for HPC in India will stem from 
application areas such as advanced drug discovery, … “ 
3. Lawrence Livermore National Laboratory A New Model for Pharma «Pharmaceutical companies 
need a faster and more accurate way to identify promising drug compounds and evaluate the 
efficacy and safety of new drugs.» 
4. Novartis Institutes for Biomedical Research Taps Cloud HPC for Faster Drug Discovery & Better 
Science 
The Novartis Institutes for Biomedical Research press release, clearly state that real HPC Virtual Screening is 
not jet integrated in the drug discovery process and, even in big pharmaceutical companies, it is so episodic 
and exceptional that a press release is needed. 
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2 AIM OF THE HERE REPORTED PH.D. STUDIES 
In the scenario given in the introduction (chapter 1), data analytics and computer simulations already form 
an integral part of the entire drug discovery and development process and will dramatically increase their 
relevance in the future as has already happened in other advanced, from a computational point of view, 
sectors such as material science and the aerospace/automotive fields.   
My PhD project findings have their major application in the early phase of the drug discovery process, in 
particular we have developed and validated two computational tools (Molecular Assembles and LiGen) to 
support the hit finding and the hit to lead phases. 
I have reported here novel methods to first design chemical libraries optimized for HTS and then profile 
them for a specific target receptor or enzyme. I also analyzed the generated bio-chemical data in order to 
obtain robust SARs and to select the most promising hits for the follow up. The described methods support 
the iterative process of validated hit series optimization up to the identification of a lead.  
In chapter 3, Ligand generator (LiGen), a de novo tool for structure based virtual screening, is presented. 
The development of LiGen is a project based on a collaboration among Dompé Farmaceutici SpA, CINECA 
and the University of Parma. In this multidisciplinary group, the integration of different skills has allowed 
the development, from scratch,  of a virtual screening tool, able to compete in terms of performance with 
long standing, well-established molecular docking tools such as Glide, Autodock and PLANTS. 
LiGen, using a novel docking algorithm, is able to perform ligand flexible docking without performing a 
conformational sampling. LiGen also has other distinctive features with respect to other molecular docking 
programs: 
 LiGen uses the inverse pharmacophore derived from the binding site to identify the putative 
bioactive conformation of the molecules, thus avoiding the evaluation of molecular conformations 
which do not match the key features of the binding site.  
 LiGen implemenst a de novo molecule builder based on the accurate definition of chemical rules 
taking account of building block (reagents) reactivity. 
 LiGen is natively a multi-platform C++ portable code designed for HPC applications and optimized 
for the most recent hardware architectures like the Xeon Phi Accelerators.  
Chapter 3 also reports the further development and optimization of the software starting from the results 
obtained in the first optimization step performed to validate the software and to derive the default 
parameters. 
In chapter 4, the application of LiGen in the discovery and optimization of novel inhibitors of the 
complement factor 5 receptor (C5aR) is reported. Briefly, the C5a anaphylatoxin acting on its cognate G 
protein-coupled receptor C5aR is a potent pronociceptive mediator in several models of inflammatory and 
neuropathic pain. Although there has long been interest in the identification of C5aR inhibitors, their 
development has been complicated, as is the case with many peptidomimetic drugs, mostly due to the 
poor drug-like properties of these molecules. Herein, we report the de novo design of a potent and 
selective C5aR noncompetitive allosteric inhibitor, DF2593A. DF2593A design was guided by the hypothesis 
that an allosteric site, the “minor pocket”, previously characterized in CXCR1 and CXCR2, could be 
functionally conserved in the GPCR class.DF2593A potently inhibited C5a-induced migration of human and 
rodent neutrophils in vitro. Moreover, oral administration of DF2593A effectively reduced mechanical 
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hyperalgesia in several models of acute and chronic inflammatory and neuropathic pain in vivo, without any 
apparent side effects. 
Chapter 5 describes another tool: Molecular Assemblies (MA), a novel metrics based on a hierarchical 
representation of the molecule based on different representations of the scaffold of the molecule and 
pruning rules. 
The algorithm used by MA, defining a priori a metrics (a set of rules), creates a representation of the 
chemical structure through hierarchical decomposition of the scaffold in fragments, in a pathway invariant 
way (this feature is novel with respect to the other algorithms reported in literature) (Figure 5Error! 
Reference source not found.). 
 
Figure 5. Cystoscape plot of the pathway independent fragmentation of one of the nine representations of the reference molecule 
Such structure decomposition is applied to nine hierarchical representation of the scaffold of the reference 
molecule, differing for the content of structural information: atom typing and bond order (this feature is 
novel with respect to the other algorithms reported in literature) (Figure 6).  
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Figure 6. Cystoscape plot of the nine hierarchical representations of the reference molecule 
The algorithm (metrics) generates a multi-dimensional hierarchical representation of the molecule.   
This descriptor applied to a library of compounds is able to extract structural (molecule having the same 
scaffold, wireframe or framework) and sub structural (molecule having the same fragments in common) 
relations among all the molecules. 
At least, this method generates relations among molecules based on identities (scaffolds or fragments). 
Such an approach produces a unique representation of the reference chemical space not biased by the 
threshold used to define the similarity cut-off between two molecules. This is in contrast to other methods 
which generate representations based in similarities.  
MA procedure, retrieving all scaffold representation, fragments and fragmentation’s patterns (according to 
the predefined rules) from a molecule, creates a molecular descriptor useful for several cheminformatics 
applications: 
 Visualization of the chemical space. The scaffold relations (Figure 7) and the fragmentation patterns 
can be plotted using a network representation. The obtained graphs are useful depictions of the 
chemical space highlighting the relations that occur among the molecule in a two dimensional 
space. 
 Clustering of the chemical space. The relations among the molecules are based on identities. This 
means that the scaffold representations and their fragments can be used as a hierarchical 
clustering method. This descriptor produces clusters that are independent from the number and 
similarity among closest neighbors because belonging to a cluster is a property of the single 
molecule (Figure 8). This intrinsic feature makes the scaffold based clustering much faster than 
other methods in producing “stable” clusters in fact, adding and removing molecules increases and 
decreases the number of clusters while adding or removing relations among the clusters. However 
these changes do not affect the cluster number and the relation of the other molecules in dataset. 
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 Generate scaffold-based fingerprints. The descriptor can be used as a fingerprint of the molecule 
and to generate a similarity index able to compare single molecules or also to compare the diversity 
of two libraries as a whole. 
 
Figure 7. Cystoscape Plot of the network of structural relationships generate by the Molecular Assemblies descriptor 
 
Figure 8. Cystoscape Plot of the clusters generated using the Molecular Assemblies metrics on 454 COX2 Inhibitors. Highlighted the 
most relevant cluster accounting for the "coxib" class of molecules 
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Chapter 6 reports an application of MA in the design of a diverse drug-like scaffold based library optimized 
for HTS campaigns. A well designed, sizeable and properly organized chemical library is a fundamental 
prerequisite for any HTS project. To build a collection of chemical compounds with high chemical diversity 
was the aim of the Italian Drug Discovery Network (IDDN) initiative. A structurally diverse collection of 
about 200,000 chemical molecules was designed and built taking into account practical aspects related to 
experimental HTS procedures. Algorithms and procedures were developed and implemented to address 
compound filtering, selection, clusterization and plating. 
Chapter 7 collects concluding remarks and plans for the further development of the tools
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3 LIGAND GENERATOR A DE NOVO TOOL FOR STRUCTURE BASED VIRTUAL 
SCREENING 
3.1 INTRODUCTION 
Computer Aided Drug Design and Development (CADDD) is an effective strategy for accelerating and 
economizing the drug discovery and development process as reported in Chapter 1. Because of the 
dramatic increase in the availability of biological macromolecule and small molecule information, the 
applicability of computational drug discovery has been extended and broadly applied to nearly every stage 
in the drug discovery and development workflow, including target identification and validation, lead 
discovery and optimization and preclinical tests1. 
Molecular de novo design aims to generate novel chemotypes endowed with a particular set of desired 
pharmacological properties. Indeed the properties have to be tuned specifically according to the biological 
target localization, the administration route, the metabolic profile2… The de novo design process is ideally 
driven by knowledge, knowledge is needed to define constraints to which the novel molecular structures 
being generated are supposed to obey. As extensively discussed by Schneider and  Fechner2, the search for 
novel chemotypes is a local and a multi-objective optimization process3, which can lead to several solutions 
according to the input constraints and to the generation rules chosen by the chemist. On the other hand, 
finding a globally optimal solution is unworkable given the enormous size of the available chemical space4. 
Therefore, computer programs have been actively sought during the past two decades to help (medicinal) 
chemists to find the best local solutions in terms of pharmacological properties, chemical feasibility, 
innovation, and patentability. As a result, several molecular de novo programs, such as LUDI 5, LEGEND6, 
LeapFrog7, LigBuilder 28, SPROUT9, HOOK10, PRO-LIGANDS11, DOGS12 have been developed and thorough 
reviews of the de novo programs are available2, 13. Despite several successful applications having been 
reported,14 many problems eventually prevented molecular de novo design approaches  to become 
established tools in drug design, and, in fact, methods like virtual screening and molecular docking have 
received greater attention, either in terms of successful applications or widespread use. The most relevant 
issues associated with these early de novo design methods are: i. Producing  chemical structures with poor 
drug-like properties and without any means of  synthetic feasibility: 
 Poor synthetic accessibility of the suggested  ligand15; 
 low structural diversity14; 
 Low potential for parallel synthesis applications (a part from when combinatorial chemistry is 
directly addressed16); 
Structures have the tendency to be bigger than necessary and too functionalized, because of the attempt of 
the algorithm to optimize all the possible interactions of the ligand with the binding site. 
The issue of synthetic feasibility, in particular, is the most relevant one and its impact on the outcome of 
the de novo approach is highly dependent on the stage of the project and on the size of the library that has 
to be assembled. When the main goal is an HTS primary screening campaign, many docking as well as de 
novo design programs are able to handle combinatorial explosions. 
Using a simplified procedure:  the definition of a set of fragments (reagents) with  predefined anchor points, 
and trivial linkage rules can lead to the generation of targeted libraries of arbitrary size which can  in 
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principle be synthesized in parallel. In this context, the ability to control chemistry, in terms of reaction 
steps and reagent’s availability, is crucial to moving the designed libraries from virtual to real.  
Another common application of de novo design is lead optimization. In this case, the binding mode of the 
core structure of the lead has usually already been validated and the scope of the de novo approach is to 
optimize decoration towards increased affinity and/or improved ADME properties. The value of the class 
under study is therefore high, and the number of compounds to be generated is reasonably low. Thus, the 
selection of the fragments is driven by the optimization process and not by the accessibility of the pre-
synthesized reagents. Even in this case, a simplified set of rules for the assembly of the fragments to the 
core scaffold is generally used:  synthetic feasibility is not addressed by the software itself, but by the 
medical chemist who defines the anchor points and the set of functional groups that will define the 
chemical space to explore. 
Generally used also for scaffold hopping, Ligbuilder8 and FlexX17 in combination with ReCore18, are able to 
generate new scaffolds for the same pattern of substituents.  
A relevant application is the design of ligand-based libraries without a predefined set of scaffolds. In this 
case it is imperative to extensively map the available chemical space by defining a wide set of chemical 
rules.  
Two approaches try to address the synthetic feasibility problem: the first  is to use a retro-synthetic analysis 
of the final ligand, and this is generally done by the implementation of bond breaking rules. LigBuilder28 is 
an example in which an internal database of building blocks, while it is also possible to use standalone 
programs, like for example SYLVIA19, developed by Molecular Networks. These approaches try to find and 
identity the bonds that more likely can be created by a chemical reaction and then break them. Like the 
Retrosynthetic Combinatorial Analysis Procedure (RECAP)20 allows the identification of building block 
fragments rich in biologically recognized elements and privileged motifs and structures, this approach 
generates virtual fragments without any embedded evaluation their of commercial availability. 
The second approach, used by most of the available de novo design programs uses restricted sets of 
chemical rules that encode for the most common chemical reactions. Some of the most relevant reaction 
driven de novo software’s with an extended set of chemical reactions are SYNOPSIS21 and DOGS12. 
In this scenario, we decided to develop a de novo design program able to employ a user-defined set of true 
chemical reactions as connection rules and to use tangible commercial reagents as building blocks. Ligand 
Generator (LiGen), described in this chapter, is a suite of programs able to define flexible de novo design 
workflows by using both pharmacophores and molecular docking engines, linking the fragments in situ, and 
directly scoring the drug likeness of the generated molecules. 
In a standard application, the modules work sequentially, from the generation of the input constraints 
(either structure-based, through active site identification, or ligand-based, through pharmacophore 
definition), to docking and de novo generation. Alternatively, the modules can be used as standalone 
services according to the user’s need. Figure 9 illustrates the general LiGen workflow.  
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Figure 9.schematic representation of the LiGen modules and dataflow. 
The structure and the function of individual modules are described in detail  in the following paragraphs, 
along with a general description of the philosophy and of the functionalities and of the software. Identified 
issues and implemented solutions, during the 2014 research , will also be reported. 
3.2 LIGEN’S FEATURES 
As mentioned above, the LiGen suite has been designed to be, at one and the same time, a modular de 
novo design application and a computational tool box. The LiGen modules can be used independently from 
each other and combined with other tools typically used in drug design research. 
This is possible because of how the modules communicate each other by using a few standard data formats, 
with a few minor extensions for inter-module communication not breaking the original standard format. 
Moreover the modular structure of LiGen allows the implementation of different workflows using the basic 
building block tools, depending on the specific computation or analysis required. 
LiGen is written in C++, with the use of STL (Standard Template Library) at high level, and its own algorithms 
(functions) and data structures (classes) at low level. In this way, the code is flexible, easily extensible and 
fast on many architectures. Performance portability to different hardware has been a main priority in LiGen 
design. Using STL at all levels (e.g. basic vector for interatomic distances) may result in a code not equally 
efficient on all hardware, or possibly not at all portable (think to GPU computing where CUDA or OpenCL 
kernels are required, and STL may not be fully supported). For these strategic reasons, code flexibility and 
portability to different hardware, Intel XEON PHI was selected as our platform of choice for HPC 
applications. 
All LiGen modules share the same basic C++ classes representing main biochemical objects: Atoms, 
Residues, Molecules; or Mathematical objects: vector, grid, ring, etc. LiGen modules can be compiled in 
standalone executable or built together in a single executable, implementing a given workflow. The basic 
modules of LiGen are: LiGenPass, LiGenPocket, LiGenSmiles, LiGenMD, LiGenMinimizer, LiGenSSS, 
LiGenDock, LiGenScore, and LiGenBuilder. 
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3.2.1 Definition of the Input Constraints 
The definition of the input constraints required to run a de novo design, given a biological target, is 
particularly relevant as it is directly connected to the quality evaluation of the candidate compounds which 
will eventually result from the run.  In general, target constraints for the generated compounds are 
composed by a set of information related to ligand-receptor interactions. This information may equally 
derive from the known 3D structure of the ligand-receptor complex or from the structure of a set of ligands 
for that particular target. In the common case of receptor based approaches, input constraints are usually 
given in the form of shape constraints, derived from complementarity between ligand and binding pocket,  
and in the form of potential interaction points, usually classified as hydrogen bonds, electrostatic and 
hydrophobic interactions. The thus extracted constraints are used to score the candidate compounds.  
The purpose of the scoring function is to delineate the correct poses from incorrect poses, or binders from 
inactive compounds in a reasonable computation time. However, scoring functions involve estimating, 
rather than calculating the binding affinity between the protein and ligand and through these functions, 
adopting various assumptions and simplifications22. Scoring functions can be divided into force-field-based, 
empirical and knowledge-based scoring functions23.  
Classical force-field-based scoring functions24 assess the binding energy by calculating the sum of the non-
bonded (electrostatics and van der Waals) interactions. The van der Waals terms are described by a 
Lennard-Jones potential function. Force-field-based scoring functions also present the problem of slow 
computational speed. Thus the cut-off distance is used to handle the non-bonded interactions. This also 
results in decreasing the accuracy of long-range effects involved in binding. 
Extensions of force-field-based scoring functions consider the hydrogen bonds, solvations and entropy 
contributions. Software programs, such as DOCK25, GOLD26  and AutoDock27, offer users such functions. In 
empirical scoring functions, binding energy decomposes into several energy components, such as hydrogen 
bond, ionic interaction, hydrophobic effect and binding entropy. Each component is multiplied by a 
coefficient and then summed up to give a final score. Coefficients are obtained from regression analysis 
fitted to a test set of ligand-protein complexes with known binding affinities.  
Knowledge-based scoring functions28 use statistical analysis of ligand-protein complex crystal structures to 
obtain the interatomic contact frequencies and/or distances between the ligand and protein. They are 
based on the assumption that the more favorable an interaction is, the greater the frequency of occurrence 
will be. These frequency distributions are further converted into pairwise atom-type potentials. The score is 
calculated by favoring preferred contacts and penalizing repulsive interactions between each atom in the 
ligand and protein within a given cutoff. 
Consensus scoring29 , the type implemented in LiGen, is a recent strategy that combines several different 
scores to assess the docking conformation. A pose of ligand or a potential binder could be accepted when it 
scores well under a number of different scoring schemes. Consensus scoring usually substantially improves 
enrichments in virtual screening, and improves the prediction of bound conformations and poses29b. 
LiGenPass is based upon the algorithm used by PASS (Putative Active Site with Spheres), software 
developed by Brady et al.30 to identify cavities in the target proteins. As described in the Experimental 
Section, LiGenPass is a new implementation of the algorithm and it is used by the LiGen engine to define 
binding sites for the target protein. LiGenPass characterizes regions of buried volume in the target protein 
and identifies potential binding sites based upon the size, shape and burial extent of these volumes (Figure 
10A). 
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Figure 10. Identification of protein binding sites. A) LiGenPass maps the protein surface filling cavities with probes (violet); probes 
are clustered in ASP, representing the center of mass of the cavity. B) According with the tridimensional coordinates of ASP, the 
cavity surface is mapped in order to identify hydrophobic regions (yellow), H-bind donor (blue) and H-bond acceptor (red) regions 
(key sites). C) The key sites just identified are clustered into a pharmacophore model (in orange are represented the hydrophobic 
features, in blue the H-bond donor features, in red the H-bond acceptor feature. In figure D) is shown the pharmacophore model of 
the binding site. Protein PDB code: 1dfh. Figures are prepared with Pymol.31 
Each cavity is defined by an Active Site Point (ASP) as the centre of mass of the cavity itself. The number of 
possible ASPs can be defined by the user as the threshold distance at which they are considered distinct 
units. Having identified a number of cavities through the corresponding ASPs, the user may want to 
characterize them in terms of key interaction points and suggest a pharmacophore which can subsequently 
be used for  3D database searching, docking procedure or de novo ligand computation.  
This task is performed by the LiGenPocket module. In essence, LiGenPocket works by creating a regularly 
spaced grid around ASPs, if the target protein has no co-crystallized ligands, or by defining a sphere which 
covers the ligand and the protein atoms surrounding the ligand, and then creating a grid within the sphere, 
if there is a co-crystallized ligand.   
The program then places a hydrogen atom as a probe on each grid point to check its accessibility. If the 
probe collides with the protein, that grid point will be labelled as ‘not free’. A collision is counted when the 
interatomic distance is less than the sum of van deer Waals radii reduced by 0.5 Å. If the probe does not 
collides with the protein, that grid point will be labelled as ‘free’. If a grid point is farther than 5 Å from any 
atom of the protein, it will be labelled as ‘outside’ rather than ‘free’. The assembly of free grid points forms 
the body of the binding pocket in which each newly designed ligand will be built up.  
As the next step, the program will derive key interaction sites within the binding pocket. Such information 
is necessary for the subsequent ligand construction or docking process. In the current implementation, the 
program uses three different types of probe atoms to screen the binding pocket: a positively charged sp3 
nitrogen atom (ammonium cation), representing a hydrogen bond donor; a negatively charged sp2 oxygen 
atom (as in a carboxyl group), representing a hydrogen bond acceptor; a sp3 carbon atom (methane), 
representing a hydrophobic group.  For each free grid point, the binding energies between the probes and 
the protein are calculated by using an in house developed scoring function.  Each grid point will be labelled 
Development and Validation Of In Silico Tools For Efficient Library Design and Data Analysis  
in High Throughput Screening Campaigns 
Chapter 3: Ligand Generator A De Novo Tool For Structure Based Virtual Screening  
 
 
25 
 
as donor, acceptor, or hydrophobic according to the highest score achieved by one of the three probes on 
that particular point. The program will then filter all the grid points to derive the key interaction sites in a 
two-step process. In the first step, the program calculates the average score for all the grid points labelled 
as ‘donor’. Then the program identifies grid points having a score lower than the average and labels them 
back as free. The same process is repeated for the ‘acceptor’ grid points and for the ‘hydrophobic’ grid 
points (Figure 10B). At this stage, LiGenPocket attempts a definition of pharmacophoric points. Each 
Surviving grid point, either donor, acceptor, or hydrophobic, is characterized for the number of ‘neighbour’ 
grid points. In this context, ‘neighbours’ are defined as grid points with the same definition (donor, 
acceptor, or hydrophobic), falling less than 2 Å from that particular point. The average of neighbours for 
each type of grid points is calculated, and those points having a number of neighbours lower than the 
average are labelled as free. After this step, only those grid points that ‘aggregate’ survive, and can be 
defined as the key interaction sites within the binding pocket. The geometric centre of each aggregation is 
calculated and finally defined as a pharmacophoric point (donor, acceptor, or hydrophobic) (Figure 10C).  
This binding site-derived pharmacophore model can then be used for the subsequent docking of candidate 
compounds, or directly as a query structure to perform 3D database searching, which provides an 
additional way to find novel ligand molecules that fit to the target protein.  
3.2.2 Docking Procedures 
In a standard application of a de novo design approach, placement of fragments into the target protein 
according to a set of input constraints usually follows the characterization of the binding pocket(s). LiGen 
accomplishes this task by using the module LiGenDock, which can also be used as a standalone module to 
perform classical docking experiments. The main feature of LiGenDock is the use of the pharmacophore 
scheme generated by LiGenPocket as the driver for the docking procedure, including a non-enumerative 
flexible docking algorithm (Figure 11). 
 
Figure 11. LiGenDock process workflow.  
A through description of LiGenDock, along with its full validation and with the optimization of the docking 
parameters, is presented in a recent publication of our group32.  
3.2.2.1 Docking Algorithm 
 Step 1. Aligns rigidly the center of mass of the ligand with the center of mass of the cavity (Figure 
12B). 
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 Step 2. All possible combination pairs between the pharmacophoric points defined by LiGenPocket 
the interacting atoms on the ligand, in this step the ligand in considered as a rigid body (Figure 12C). 
 Step 3.  A conformer search is performed, allowing all torsional angles to rotate freely. The 
conformers with the best scores are retained for the successive step (Figure 12D). 
 Step 4. loops over all ligand poses that match two pairs of pharmacophore feature-ligand atoms, 
trying to match a third pair by rotating the ligand around the axis connecting the two pairs already 
found (Figure 12D). 
 Step 5. Exits the procedure by keeping the best poses of the ligand, which are then passed to an 
energy minimization, routine used to refine the position of the ligand inside the binding pocket 
(Figure 12E). 
 
 
Figure 12. Cartoon of the workflow of the docking algorithm as originally implemented in LiGenDock. when the rigid placement of 
the ligand (Step 1 and 2) generates poses having a good overlap with the binding site and with the receptor’s pharmacophore. 
 This algorithms has demonstrated good performance in a wide range of situations32b, comparable with 
other docking programs such as Autodock, Glide and PLANTS33. 
In the routine use of the software in our lab, we found that the performance of LiGenDiock (using default 
parameters) with very flexible ligands in combination with particular binding pockets is very poor when 
trying to identify the correct pose of the ligand with respect to the experimentally determined one. In some 
cases the results greatly improve by tuning, the parameters of the docking engine do control the flexible 
part of the docking procedure (steps 3 and 4). The novel set of the parameters has the drawback of 
dramatically increasing the docking time (from 30 seconds per molecules to several minutes).  
Therefore, we decided to investigate this set of “difficult” cases. After an extensive exploration of the 
docking parameters, we were able to isolate the problem. In Figure 13, we can see a schematic 
representation of the occurring issue. When the 3D conformation of the ligand differs too much from the 
shape of the cavity of the binding site the first rigid placement of the ligand (step 1 and 2) produces starting 
poses presenting too many clashes with the target protein and with a suboptimal alignment of the ligand 
with the receptor pharmacophore (Figure 13B). In this scenario, the generation of a good pose is devoted 
to the flexible part of the docking algorithm (Figure 13D) (step 3 and 4) and the optimal set of parameters is 
dependent on the specific ligand/site complex, this specificity prevents the implementation of a set of 
parameters able to correctly address this particular condition. In addition the step 3 and 4 of the docking 
process: the flexible pharmacophore refinement of the pose, are meant to find local minima, in this 
circumstance the algorithm is forced to find a global minima. The result is that the docking time increases 3 
to 5 fold, with an average docking time shifted from 30 seconds to 2 minutes per molecule, this docking 
time is too high to use the software for HPC applications. 
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Figure 13. Cartoon of the workflow of the docking algorithm as originally implemented in LiGenDock, when the rigid placement of 
the ligand (Step 1 and 2) generates poses having a poor overlap with the binding site and with the receptor’s pharmacophore. 
We decided to address this limitation of the docking algorithm by redesigning from scratch the rigid 
placement of the ligand (steps 1 and 2). We found an interesting opportunity in the shape of 
complementarity methods.  
Geometric matching/shape complementarity methods describe the protein and ligand as a set of features 
that make them dockable34. These features may include molecular surface/complementary surface 
descriptors like LigandFit35. In this case, the receptor’s molecular surface is described in terms of its solvent 
- accessible surface area and the ligand’s molecular surface is described in terms of its matching surface 
description36. The complementarity between the two surfaces amounts to the shape matching description 
that may help find the complementary pose of docking the target and the ligand molecules. Another 
approach is to use a Fourier shape descriptor technique37. Whereas the shape complementarity based 
approaches are typically fast and robust, they cannot usually model the movements or dynamic changes in 
the ligand/ protein conformations accurately, although recent developments allow these methods to 
investigate ligand flexibility.  
Shape complementarity methods can quickly scan through several thousand ligands in a matter of seconds 
and actually figure out whether they can bind at the protein’s active site, and are usually scalable to even 
protein – protein interactions38. 
By what means shape complementarity methods are good in the prediction of a bioactive conformation, 
has been recently assessed by Renxiao Wang group, Li et al39 tested a panel of 20 scoring functions. They 
introduced a naïve scoring function as a reference, the buried solvent accessible surface area of the ligand 
molecule upon binding (ΔSAS). ΔSAS is an estimation of the size of the protein− ligand binding interface. 
They observed that ΔSAS outperformed most scoring functions in the scoring test39. This embarrassing fact 
indicates that current scoring functions have not advanced too far from very simple accounts of 
protein−ligand interactions. It also suggests that the major problem in computing ligand binding affinities 
does not lie in the nonpolar aspect. Nonpolar interactions are conventionally modeled by the non-
discriminative contacting surface area, and many scoring functions actually have such an account explicitly 
or implicitly. Instead, polar interactions, as well as the desolvation effect associated with them, remain as 
the real challenge. Besides, its performance in the docking of the directory of useful decoy (DUD) 
database40 is virtually the worst among all scoring functions under evaluation. ΔSAS is a descriptor of the 
nonpolar factors in protein−ligand interactions, which are non-discriminative in nature. Therefore, it is not 
Development and Validation Of In Silico Tools For Efficient Library Design and Data Analysis  
in High Throughput Screening Campaigns 
Chapter 3: Ligand Generator A De Novo Tool For Structure Based Virtual Screening  
 
 
28 
 
really capable of differentiating the decoys from the true binding pose since they are in fact the same 
ligand molecule. To achieve a good docking power, a scoring function needs necessary consideration of 
specific, directional polar interactions, such as hydrogen bonds.  
For our scope, the reimplementation of the algorithm for the identification of the initial pool of starting 
poses, the limitation highlighted by  Li et al39 is not relevant because the shape complementarity method is 
only the first step of LiGenDock. The identified poses are then flexibly aligned to the receptor 
pharmacophore (Step 3 and 4) and finally the interactions occurring with the receptor are evaluated by a 
consensus scoring function LiGenScore. Therefore, for us the relevant information is that this method is 
able to identify bioactive conformations. 
Two new algorithm based on spatial geometry of the pharmacophore and topology of the ligand have been 
introduced to address two problems: 
 the independency of the docking result from the initial configuration of the ligand, and the shape 
matching bedween ligand and volume available inside the protein pocket. 
 The first algorithm is a minimization algorithm that perform an unfold of the ligand using all 
rotational degrees of freedom, with the objective of maximizing the sum of all distance between 
ligand atoms. 
 Moreover there is the option to relax the atomic bonds and angles using mff94 force field data. 
The second algorithm uses the probe atoms that have been used to define the pochet as the definition of 
the target volume to be maximally occupied by the ligand. The procedure is iterative and start computing 
the center of mass and moments of inertia of the probe atoms (using a fake atomic mass equal for all 
probes), then the algorithm do the same for the unfolded ligand (using the same fake atomic mass as for 
the probes, and regardless of the atomic type), after that the algorithm proceed aligning the center of mass 
of the ligands with the probes and then rotate the ligands so that the inertia axis of the ligand are aligned 
with the inertia axis of the probes. 
Finally a procedure similar to the algorithm used to unfold the ligand is used to optimize the geometry of 
the ligand to match the magnitude of the inertia axis of the probe set. The optimal result is a ligand whose 
shape match those of the probe. Obviously this is an ideal situation, in reality, since the space of 
configuration has a lot of local minima, the procedure; most of the time will find a sub-optimal 
configuration with the solution in one of this local minima. The solution could be eventually improved using 
a simulated annealing procedure (or some other technique to find global minima), but the procedure risk 
then to become costly in term of compute time. A local minima, in this specific contest, is enough most of 
the time for our goal 
3.2.3 Reproducibility of the docking results 
One of the most relevant strength of the docking engine should be the reproducibility of the docking poses. 
The implemented algorithm in LiGenDock is completely deterministic. To test the stability of the engine we 
have rerun LiGenDock (original implementation of the algorithm) with the same parameters and the same 
3D structure (((3R)-3-amino-4-[(3-hexylphenyl)amino]-4- oxobutyl)phosphonic acid as bound to S1PR1 (PDB 
ID: 3V2Y) ) of the same ligand 455 times. Results are reported in Figure 14, the software generates exactly 
the same pose in all the runs. 
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Figure 14. Score values distribution plot generated by LiGen in the re-dock of 455 the same conformer test 
To compare these results with other docking programs: we report in Figure 15  the results of VINA software 
and in Figure 16 the Autodock results. 
 
Figure 15. Score values distribution plot generated by VINA in the re-dock of 455 the same conformer test 
 
Figure 16. Score values distribution plot generated by Autodock in the re-dock of 455 the same conformer test 
The stochastic docking engine of VINA generate an ensemble of solutions with a standard deviation of 1.25 
units of score values and Autodock’s score values spread in a range of 3.3 score units. 
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The stability of LiGen re-dock versus the other docking software is for obvious reasons a remarkable feature. 
To test the dependency of the software from the starting conformation, we selected a very flexible ligand 
with nine rotatable bonds. 
We generated for the (((3R)-3-amino-4-[(3-hexylphenyl)amino]-4- oxobutyl)phosphonic acid as bound to 
S1PR1 (PDB ID: 3V2Y) 455 diverse conformers. Then we docked the ligand conformations in the reference 
target with LiGen, original implementation of the algorithm (Figure 17), VINA (Figure 18) and Autodock 
(Figure 19). 
 
Figure 17. Score values distribution plot generated by LiGen in the dock of 455 the diverse conformer test 
 
Figure 18. Score values distribution plot generated by VINA in the dock of 455 the diverse conformer test 
 
Figure 19. Score values distribution plot generated by VINA in the dock of 455 the diverse conformer test 
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The effect of the starting conformation on the range of values in the scoring function is 1.4 with LiGen, 1.5 
with VINA and 3.6 with AutoDock. VINA in the two stability tests (re-dock of the same conformer 455 times 
and dock of 455 most diverse conformers), produces almost the same  score frequency distribution plot 
(Figure 20). It means that, the bias introduced by the stochastic search has the same effect and magnitude 
on the results as a careful sampling of the conformational space of the ligand. 
 
Figure 20. Score values distribution plot generated by VINA for the two stability tests 
Even if LiGen has the lower oscillation in the results, it is nevertheless unacceptable for our stability criteria. 
In a virtual screening campaign, where the n-top percent is selected for the actual experimental validation, 
the initial conformation of the ligand introduces a strong bias to the results. This bias in LiGen could be 
reduced if an ensemble of conformation is evaluated instead of a single conformation, (for the other 
software evaluated, the fluctuation of the results is intrinsic in the stochastic nature of the docking 
algorithm and cannot be avoided). LiGen is meant for massive virtual screening campaigns and by design, it 
is implemented to avoid conformational sampling of the standalone ligand. 
As mentioned in the previous paragraph, we decided to remove this bias by the implementation of a novel 
algorithm based on shape complementarity method. Preliminary results on the reference ligand receptor 
complex show that the conformational bias can be reduced at 0.6 score units the variability range of the 
results; generate better results with a window of values between 6.8 and 6.2. 
3.2.4 Improving Pose/Compound Selection 
Due to the poor performance of current scoring functions in estimating binding affinity and hence in 
ranking docked ligands, it is recognized that compound selection based on calculated scores is not sufficient 
and visual inspection is often necessary. However, a practical concern arises if one needs to manually 
inspect thousands of docking poses41. Therefore, huge efforts have been devoted to automating this 
procedure based on the indications gained from ligand–target interactions. The molecular interaction 
fingerprints (IFPs), which are simple bit strings that encode 3D information about ligand– target 
interactions into 1D binary vector, have been extended by Marcou and Rognan as a post-docking filter to 
prioritize the most relevant poses of low molecular weight fragments42. In their study, IFPs were evaluated 
with four popular docking tools (FlexX, Glide, Gold, and Surflex) for extracting the scaffolds of true CDK2 
inhibitors. They observed that scoring by the Tanimoto similarity of IFPs to a given reference was 
statistically superior to conventional scoring functions in placing the low molecular weight fragment in the 
CDK2 binding site. Based on the assumption that active compounds should have specific contacts with their 
target to display activity and also to tackle the inefficiency of traditional clustering of docking poses, 
Bouvier et al. have proposed the Automatic analysis of Poses using  a Self-Organizing Map (AuPosSOM) 
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method for pose ranking with careful analysis of interatomic contacts between the docked ligand and the 
target43. They have demonstrated that it is possible to differentiate active compounds from inactive ones 
using only mean protein contacts’ footprints calculated from the multiple conformations given by docking 
software. 
In this scenario, we decided to embed directly in docking procedure the use of the inverse pharmacophore 
(the pharmacophore generated by the receptor interaction maps), as described in the paragraph Docking 
Procedures (3.2.2). Matching the receptor’s pharmacophore assures that in all the selected poses the 
chemical features are complementary to the key interaction site in the binding pocket. 
During the third year of my PhD, we further extended and exploited the use of the pharmacophoric 
features mapping. 
This descriptor can be used in data post-processing to select the subset of poses / ligands engaging specific 
interactions with the binding site. Pharmacophoric features mapping can be used as knowledge based on a 
hard filter of compounds to not establish required interactions with the receptor for example with enzymes. 
Alternatively, it can be used to create a model able to further enrich the number of active compounds in 
virtual screening campaigns selecting compounds able to interact with the same pharmacophoric points of 
the reference active ligands. At this stage, we are evaluating recursive-partitioning methods to generate 
discriminative models from the inverse pharmacophoric features mapping (Figure 21). 
 
Figure 21. Recursive partitioning model based on the inverse pharmacophore features mapping 
The results, on the effect of the combined model scoring function /recursive partitioning, we have obtained 
so far are too preliminary to be presented hire.  
3.2.5 Structure Generation and Synthetic Accessibility 
Several strategies can be adopted to sample and generate structures by de novo approaches. They are 
usually referred to as linking5, 8, growing44, lattice-based sampling,  random structure mutation, transitions 
driven by molecular dynamics simulations, graph-based sampling2, the former two having received 
particular attention.  The linking approach starts with fragments positioned or pre-docked at different 
interaction sites of the binding pocket. Then, the fragments are linked together to give a molecule able to 
satisfy to the greatest extent all the interaction points. Also the growing approach starts with a positioned 
fragment which is grown to maximize favourable interactions with the key interaction sites or with receptor 
regions in between key interaction sites. 
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The basic building blocks for the assembly of candidate structures can be either single atoms or fragments. 
Atom-based approaches are superior to fragment-based methods in terms of the structural variety that can 
be generated, but this increase in potential solutions makes it harder to find feasible and druggable 
candidate compounds among the ones that have been identified.  LiGen implements the structure building 
in a way that effectively ensures the synthetic feasibility of the candidate compounds. The building model 
of LiGen, called LiGenBuilder, is at the heart of LiGen and is the main engine implementing our de-novo 
algorithm. In particular, LiGenBuilder is combined with the docking (LiGenDock) and the force field engine 
(LiGenMD) modules to cooperate in order to perform in situ de novo growth of novel ligands. The building 
algorithm implemented in LiGenBuilder is described in detail in the next paragraph. 
3.2.5.1 De Novo Design 
In Figure 22.The overall process of ligand growth is presented.  
 
Figure 22. De novo design process of LiGen. Black boxes represents modules before LiGenBuilder 
The process starts with a pre-building step (Figure 22.A) where a set of fragments is docked into the target 
active site and a number of poses that match given criteria are retained into a set which will be used as a 
basis for the successive growth process. In detail, seed building blocks are assigned with force field 
parameters (MMFF9445) and minimized (geometry optimization using MMFF94 force field).  The building 
block atoms are also tagged for all possible reactions defined in a chemical rules database. Seed building 
blocks are then passed through three sub-phases. The first one is rigid docking, where the fragments are 
placed inside the pocket using the scoring function and the best poses kept in the seed set of poses; then 
the torsional angle of the poses are allowed to move so that the poses can be further optimized to lower 
the binding energy with the target protein; finally the complexes between poses and the target protein are 
minimized to find a local energy minimum. A pose is kept inside the set of best poses if the difference 
between internal energy before and after the minimization inside the pocket is less than a given threshold 
(defined by the user). 
After this starting set has been completed,  the process continues with a sequence of building steps (Figure 
5B) where the poses contained in the starting set are grown by using building blocks selected randomly 
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(according to a probability  function that depend on the chemical rules) among all the fragments that can 
react with the pose.  
The new fragments thus formed are then docked again inside the protein pocket and the growing cycle 
continues. The process ends when either all the possible combinations of fragments have been explored 
(very rare event) or the molecular weight of the candidate ligand (pose) is larger than a user-defined value 
(Figure 23).  
 
Figure 23. Example of ligand growing process. A) and B) placement of the fragments inside the binding site in order to match the 
features of the pharmacophore; C) different fragments shown together in the binding site, matching different pharmacophore 
features; D) the final generated ligand is minimized inside the binding site in order to catch the most favorable interactions (in 
orange is represented the generated ligand, in blue the co-crystallize ligand pose). PDBcode of the example complex: 1kv1. Figures 
are prepared with Pymol31.   
3.2.5.2 Chemical Rule Database 
To perform the linking of two fragments or building blocks, a database of the most frequently established 
chemical reactions in parallel and combinatorial chemistry is used. The database has been encoded using 
the MDL mol format tagging the atoms with labels.  
Two kinds of labels have been implemented: the part of the molecule that will be not present in the 
product is tagged with “<Clip>” and the reactive point for the reaction is labelled with an atom 
environment description tag. For example a reactive chlorine on a phenyl ring is tagged as “<Ph.Cl1>”. 
Other examples of tagged structures are presented in Figure 24 
 
Figure 24. Examples of tagged chemical structures. 
The key step of the de novo design process is now the transfer of the set of reactive points to the set of 
fragments or building blocks. Unlike other software like LigBuilder8, LiGen does not need a pre-tagged 
database of fragments. On the contrary, an arbitrary database of fragments can be used without 
manipulation in the de novo process. This feature is provided by the LiGenSSS module (Figure 25). 
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Figure 25. Example of how LiGenSSS works. It transfers tags from the reactive point database to the fragment database used in the 
de novo design process.   
LiGenSSS carries out a substructure search in the database of fragments and identifies the reactive part of 
the building block. Once a match between a fragment substructure and a reactive point is found, LiGenSSS 
transfers the tag(s) from the reactive point database to the matched structure in the fragment database. As 
a result, a database of tagged reagents (building blocks) is available. 
The assembly of reactants is carried out, in a stepwise process, by LiGenBuilder. LiGenBuilder reads a text 
file where a simple linear notation for all the possible defined chemical reactions is encoded. Figure 26 
shows the part of this reaction file for a Suzuki coupling reaction.  
 
Figure 26. Example of a reaction file (a Suzuki coupling reaction). 
The user can edit the file to encode pairs of reacting groups. It is also possible to control the distribution of 
the chemical reactions in the library. For instance, column five of the reaction file controls the probability 
that a given reaction will be cast by the LiGenBuilder grow engine. According to the example given in Figure 
26, a Suzuki coupling has a 50%  probability of being selected. Among all the possible Suzuki couplings, the 
aryl-Bromine derivative has a 60% chance of being selected versus the other two reactants. On the other 
hand, the sterically hindered chlorine derivatives [Ar.Cl2] will be used only if reagents with a higher 
reactivity are not available. 
Useing defined casting rules allows  guidance of the chemistry of the library, for example limiting the 
number of synthetic routes or focusing first on compounds having the higher chance to be successfully 
synthetized.  
DISCUSSION 
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Despite their theoretical very high relevance, de novo design methods did not become established tools in 
drug design because of the presence of several drawbacks that limited their application to real world cases. 
LiGen, the suite of programs described in this paper, aims at addressing most of the issues associated with 
available de novo design approaches. Key features of LiGen are: i) pharmacophoric constraints are 
implemented in the pose identification. This allows the obtaining of only the poses endowed with the 
correct pattern of interactions with the binding pocket, and therefore  significantly reduces the time for 
filtering them out once generated, as it is done by most of the docking programs and  time  is needed for 
visual inspection.  (ii) Flexible docking without conformer enumeration. Even for molecules with a few 
rotatable bonds, the coverage of the conformational space accomplished by enumerative methods, is only 
partial. Thus, docking methods based on conformational sampling are biased by the degree of coverage of 
the conformational space. Flexible alignment of the molecule on the pharmacophore points eliminates this 
bias and produces the bioactive conformation of the molecule, as long as the interaction points are 
correctly defined. If energetically allowed, this conformation is retained. If not, the molecule is discarded as 
unable to match the possible pharmacophoric mappings. This minimizes the number of molecular 
conformations which are evaluated for each ligand. A detailed description and optimization of the docking 
routines is presented in an accompanying paper. (iii)  Accurate and flexible reactant mapping. Although 
many excellent de novo design softwares effectively handle chemical rules (for example DOGS12), LiGen 
stands out by allowing the user to prioritize the chemical reactions through the definition of a probability of 
a reaction class (in the example, Suzuki coupling has a 50% of chance of being selected among all other 
reactions) and the definition of a probability of a reactive group meaning that if a building block is present 
such as bromine and chloride derivatives the most reactive one has more chance of being selected by the 
system to form the final molecule. This fine tuning allows the smallest number of chemical reactions to 
synthesize the de novo library with the selection of the most promising building blocks in terms of success 
of synthesis and yields. 
(iv) Reactant tagging through substructure searching. In this way, the library of building blocks, fragments, 
or reagents, does not need to be manually tagged. Having defined the reactive chemical points, a 
substructure search routine automatically transfers the tag(s) to the fragment library. The identification of 
novel reactive points of the definition of subgroups is straightforward. 
(v) Modular architecture. Although LiGen was intended to be a suite of programs aimed at de novo design, 
it can also be used in a modular fashion, thus allowing each module to be used as a standalone tool, or to 
combine different modules to assemble task-specific  workflows. For example it is possible to define a 
workflow just to enumerate a de novo library according to defined chemical rules and used again the 
LiGenSSS to filter out unwanted combination of building blocks Figure 27. 
Interestingly, the LiGen source code has been written in such a way that a given workflow can be composed 
either by a pipe of different executable or can be compiled in a single embedded binary executable Figure 
27. 
In conclusion, we presented a new method for de novo design based on pharmacophore-driven docking 
and accurate chemical reaction mapping and implemented to be suitable for HPC applications and portable 
to many hardware architectures. 
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Figure 27. Example of a user-defined LiGen workflow. In this example the workflow was composed to enumerate a de novo library 
according to user-defined chemical rules and to exclude from this library unwanted combination of building blocks (i.e. possible new 
molecules)  running again, after LiGenBuilder, the LiGenSSS module. 
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4 TARGETING THE MINOR POCKET OF C5AR FOR THE RATIONAL DESIGN OF AN 
ORAL AVAILABLE ALLOSTERIC INHIBITOR  
4.1 INTRODUCTION 
Inflammatory and neuropathic pain are the most prevalent types of pathological pain and represent 
important health problems. Whereas inflammatory pain is one of the classical symptoms of the 
inflammatory process, neuropathic pain arises from any of multiple nerve lesions or diseases with 
symptoms including hyperalgesia or allodynia.1,2 Some of the most powerful painkillers, including opioids 
and non-steroidal anti-inflammatory drugs, are only partially effective and prolonged exposure can cause 
unwanted effects.3 4 As a result, there is continuous effort to identify novel therapeutics for pain control 
with alternative biological mechanisms and that elicit fewer side effects. 
Inflammatory mediators, including cytokines/chemokines, play a critical role in the pathogenesis of 
inflammatory and neuropathic pain.5,6 Emerging evidence suggests that C5a, the anaphylatoxin produced 
by complement activation, has potent nociceptive activity in several models of inflammatory and 
neuropathic pain by interacting with its selective receptor C5aR.7 8 C5aR belongs to the class A subfamily of 
the seven-transmembrane G protein-coupled receptors (7TM GPCR)9 and is widely expressed in immune 
cells, including neutrophils (PMN), monocytes, microglia, and in non-immune cells, including neurons in the 
central nervous system (CNS) and dorsal root ganglia (DRG).10 11 
Evidence for a role of C5a in nociception sensitization has been obtained in several models of inflammatory 
pain. For instance, C5a was produced at the inflammatory sites and elicited mechanical hyperalgesia by 
activating the C5aR on infiltrated PMN.7 Direct intraplantar injection of C5a in mice elicited both heat and 
mechanical hyperalgesia by sensitizing primary afferent C-nociceptors.12 13 Local activation of C5aR has also 
been implicated in the pathogenesis of postsurgical pain, a model of postoperative pain.13 Finally, local 
administration of PMX-53, a C5aR antagonist, attenuated mechanical hyperalgesia induced by carrageenan, 
zymosan, or lipopolysaccharide.7 In addition to the peripheral role of C5a/C5aR in inflammatory pain, up-
regulated levels of C5 and C5aR have been found in spinal cord microglia in animals subjected to spared 
nerve injury (SNI), a model of neuropathic pain.8 Indeed, C5 null mice or the infusion of PMX-53 into the 
intrathecal space reduced neuropathic pain hypersensitivity in the SNI model.8 Collectively, these data 
suggest that a neuroimmune interaction in the periphery and spinal cord through activation of the 
complement cascade and the production of C5a contributes to the genesis of both inflammatory and 
neuropathic pain.  
As for other peptidergic GPCRs, the efforts to identify small molecular weight C5aR antagonists have led to 
a limited number of molecules, mostly lacking adequate potency and selectivity.14 The most promising 
candidate so far described, PMX53, is a cyclic peptidomimetic antagonist, designed to mimic the C-terminal 
portion of C5a.15 Despite the encouraging results obtained in preclinical studies, as with many peptide 
drugs, the development of PMX53 has been limited by its short half-life and unfavorable bioavailability.16 In 
the present study, we report the successful design of a novel non-peptidic C5a allosteric small molecular 
weight (SMW) inhibitor driven by the structural information on a minor pocket spanning between TM1, 2, 
3, 6 and7 that is highly conserved across the GPCR family and that has been recently proposed as a key 
motif for the intracellular activation process Reparixin was previously reported as a neutral allosteric 
inhibitor of CXCR1 and CXCR2 that binds the TM in a region that overlaps the minor pocket.17 18 Combining 
the information from independent sources on structural and functional features of allosteric sites in 
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homologous chemokine receptors, this paper intends to provide the first example of de novo design of a 
new class of allosteric SMW inhibitors of a GPCR not belonging to the chemokine receptors family, C5aR. 
The preclinical candidate, DF2593A, is a potent and orally active C5a noncompetitive allosteric inhibitor 
with significant antinociceptive effects in a wide range of inflammatory and neuropathic pain models.  
4.2 RESULTS 
4.2.1 Binding mode characterization of DF2593A to C5aR 
The human C5aR (hC5aR) homology model was originally built using the human CXCR1-reparixin complex 19 
as a template and subsequently refined and compared with the C5aR model built starting from the human 
CCR5 (hCCR5) crystal structure (PDB code: 4MBS), in which CCR5 is bound with the marketed HIV allosteric 
drug maraviroc.20 21 Sequence identity between hCCR5 and hC5aR is 21.3% while sequence similarity is 
52.4%. Despite a low sequence identity, the key structural features defining the minor pocket, the proline 
kink in TM2 and the water-mediated hydrogen bond network between the intracellular segments of TM1, 
2, 3, 6 and 7, is highly conserved between chemokine receptors and C5aR. With the aim of developing a 
specific site-binding model in C5aR, the pattern of polar interactions involved in the anchorage of reparixin 
at CXCR1 was analyzed in detail.19 Two out of the three key residues of TM 3, 6 and 7 (Asn1203.35, Tyr2586.51 
and Glu2917.39) are fully conserved (Asn1193.35 and Tyr2586.51) in C5aR,19 22 and the glutamic residue 7.39 
(Val2847.39 in C5aR) is replaced by Asp2827.35 one helix turn above (Figure 28A and Table 2).  
 
Figure 28. DF2593A is a selective noncompetitive allosteric inhibitor of C5aR. (A) 2D structure of DF2593A. (B) 2D representation 
of DF2593A binding mode inside C5aR. Pink, green/blue and orange lines represent respectively: charge-charge interaction, H-
bond/Halogen-bond interaction, Pi-Pi and sigma interactions. (C) 3D representation of DF2593A in the TM region of C5aR (violet). 
Interacting residues are shown using the following color scheme: C(green), N(blue), O(red), S(yellow), F(cyan) and H(white); labeling 
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is based on Ballesteros-Weinstein numbering scheme. (D) Effect of DF2593A on the C5a-induced migration of wt (●), L41A (○), F93A 
(□), I96A (▲), L278A (▼), N119A (▽), and Y258A (■) C5aR/L1.2 transfectants preincubated with indicated DF2593A concentrations 
and then stimulated with 10 nM of C5a for 4 h. All mutants show a significant (p>0.05) resistance to DF2593A at all doses tested as 
compared to wild-type C5aR transfectants (E) Effect of DF2593A on the C5a-induced migration of human PMN preincubated for 15 
-desarg (○), 10 nM CXCL1 (□), 1 
nM CXCL8 (▲), 10 nM CXCL12 (△), 30 nM CCL3 (▼), and 10 nM fMLP (▼) for 1 h. (F) Effect of DF2593A on the C5a-induced 
migration of human (■), mouse (○) and rat (●) PMN preincubated with indicated DF2593A concentrations and then stimulated with 
10 nM C5a of corresponding origin. (G) Hum
of [125I]-C5a and serial dilution of cold C5a were added to 106 cells in 100 mL of binding medium. (H) Human PMN were directly 
exposed to vehicle or different concentrations of DF2593A (○) and then aliquots of 0.2 nM of [125I]-C5a and vehicle (DF2593A-treated 
PMN) or serial dilution of unlabeled C5a (vehicle-treated PMN) (●) were added to 106 cells in 100 mL of binding medium. In panels D 
to F data are expressed as % of migrated cells observed in the absence of DF2593A (mean ± S.D. of three independent experiments). 
**P < 0.01 versus cell migration in the absence of DF2593A by Mann–Whitney U-test. In panels G and H data are reported as mean 
± S.D. of three independent experiments. 
Table 2 
 
Sequence alignment of key polar residues among CXCR1/2 and C5aR.Two out of the three key polar residues (Asn1203.35, 
Tyr2586.51 and Glu2917.39) of CXCR1 are conservatively replaced (Asn1193.35 and Tyr2586.51) in C5aR, whereas the lack of the 
glutamate in position 7.39 (Val2847.39 in C5aR) is compensated by Asp2827.35. Uniprot ID codes are provided in brackets. Amino 
acids are color coded by type: red, acidic residues; green, hydrophobic aliphatic residues; blue, aromatic residues; violet, non-
charged polar residues. 
Furthermore, as for CXCR1, the minor pocket in C5aR is surrounded by a large cluster of hydrophobic 
residues (Leu411.36, Phe932.61, Ile962.64 and Leu2787.31) in the upper region of the TM layer (Fig. 1C).  
Interestingly, Asp822.50, the crucial amino acid in the conserved motif of TM2: L92%XXXD91% is also present in 
the binding cavity of C5aR.23 The formation of a hydrogen bond between Asp822.50 and Asn2967.49 in TM7 is 
deemed crucial to activate C5aR.24 Accordingly, the freezing of Asp822.50 in the inactive position with 
DF2593A may prevent the crucial movement to switch C5aR to its active state and it may represent a 
mechanistic explanation for the inhibitory effect of DF2593A. 
Based on these structural characteristics, a site-targeting library was designed to identify a new class of 
allosteric C5aR modulators. The phenylpropionic moiety was chosen as a privileged scaffold to 
accommodate the shallow crevice between TM2, 3, 6 and 7 and the trifluoromethyl group in the para 
position was selected as a promising substituent to establish a bidentate interaction with Asn1193.35 and 
Asp822.50 bridging TM3 and TM2 associated with the feature of the trifluoromethyl portion to engage 
additional hydrophobic interactions 25 26 Table 3, 1).  
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Table 3. 
 
Seeking the key polar interactions with Asp2827.35 and Tyr2586.51, a series of carboxamide and 
aminocarbonyl residues bearing basic groups were synthesized. Flexible tertiary -aminoalkylamides (Table 
3, 2-3) were Found to be dual significant inhibitors of C5a and CXCL8 induced chemotaxis whereas the 
insertion of conformationally rigid cyclic structures led to a full selectivity versus the C5aR (Table 3, 4-5).  
The geometry and the electronic status of the amido group were previously demonstrated 25 to be key 
determinants in establishing the polar network in CXCR1/2 binding sites. Thus the simple inversion of the 
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amide group in compound 1 was sufficient to lose affinity at CXCR1/2 leading to the fully C5aR selective 
isomer 6. The optimization of the alkyl chain length and hydrophobicity (Table 3, 6-9) led to the selection of 
DF2593A (Table 3, 9) as the most promising lead for further in vitro and in vivo characterization (Figure 28B 
and Figure 28C). Extensive molecular dynamics and automatic docking runs on the C5aR/DF2593A complex 
were performed to generate a reliable binding mode hypothesis. Based on the refined model, DF2593A is 
able to bind C5aR by two principal polar interaction patterns: (1) charge-charge interaction between 
Asp2827.35and the charged nitrogen of the piperidine ring of DF2593A and (2) a network of polar 
interactions between the triflate and the couple Asn1193.35/Asp822.50. Intriguingly, halogen bond 
interactions are engaged between fluorine atoms and carbonyl oxygen of both Asn1193.35 and Asp822.50.  
The polar network is reinforced by the hydrogen bond between the carbonyl group of Ile1163.32 and the 
amide moiety of DF2593A. In addition, the phenyl ring of DF2593A is involved in a pi-pi interaction with 
Tyr2907.43. As mentioned, the binding cavity is also surrounded by hydrophobic residues, like Leu411.36, 
Phe932.61, Ile962.64, Leu2787.31 and Val2867.39 (Figure 28). It has been observed that a Val286Ala7.39 mutant 
led to a moderately inactive C5aR supporting the hypothesis of a prominent functional role of TM7.27 
The allosteric nature of the C5aR minor pocket 17 and the inhibitory activity of DF2593A were then 
investigated. Wild-type receptor and seven Ala-scanning mutants of C5aR were transiently transfected in 
L1.2 cells and tested for functionality. All mutants but Asp2827.35 were non significantly impaired in their cell 
surface expression (see Fig. S2) and sustained effective cell migration in response to C5a (see Fig. S3). 
 
Figure 29. Expression levels of C5aR mutants. Cell surface expression of wild-type (black column) and indicated point mutants (while 
columns) of C5aR transiently transfected in L1.2 cells. Results are mean ± SEM of three independent experiments. D282A-C5aR is the 
only mutant significantly impaired as compared to wild-type C5aR (p<0.01). 
Transfectants were then tested in the C5a-induced chemotaxis assay in the presence of increasing 
concentrations of DF2593A. As shown in Figure 28D, the Asn1193.35Ala mutant is fully resistant to inhibition 
by DF2593A, supporting the hypothesis that Asn1193.35 is a key residue for ligand recognition. The dramatic 
effect of Tyr2586.51Ala mutant was coherent with the ligand/receptor complex in which the interaction 
established by the phenol group is essential to orientate Asp2827.35 towards the piperidine nitrogen of 
DF2593A. Tyr2586.51 hydroxyl group could also act as a hydrogen bond donor versus the carbonyl group in 
the central amide moiety of DF2593A. According to the proposed model, also the bulky hydrophobic 
Leu411.36, Phe932.61, Ile962.64Ala and Leu2787.31, even though not directly involved in ligand binding, are 
structural and energetic determinants of the hydrophobic domain governing the pattern of interactions 
within the hydrophobic cluster. The replacement of these residues with Ala profoundly alters the shape and 
size of the pocket and coherently significantly compromises DF2593A potency. Notably, sequence 
alignment confirmed that key residues involved in the putative DF2593A binding mode are well conserved 
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in both rat and mouse orthologs supporting the potential of the candidate for further preclinical 
pharmacology studies (Figure 30). 
 
Figure 30. Sequence alignment of human, mouse and rat C5aR. Asn1203.35 and Tyr2586.51 are fully conservatively in the C5aR 
orthologs, whereas Asp2827.35 is replaced by Asn7.35 in both the orthologs. Hydrophobic residues, Leu411.36 and Phe932.61 are 
also fully conserved in mouse and rat C5aR. Ile962.64 is conserved in rat (Ile972.64) and is replaced by Val932.64 in mouse C5aR. 
Leu278 7.31 is replaced by a similar hydrophobic residue, Val2767.31 and Val2807.31, in mouse and rat respectively. Key residues of 
the allosteric pocket are shown in black boxes with Weinstein Ballesteros annotation. Uniprot ID codes are provided. 
 
4.2.2 In vitro characterization of DF2593A 
Pharmacological characterization showed that DF2593A did not inhibit spontaneous cell migration per se 
and was > 1000-fold selective versus other chemoattractants, including CXCL8 and CXCL1 (IC50 > 10 M) (Fig. 
1E). DF2593A effectively inhibited C5a-induced human PMN migration (IC50 = 5.0 nM) and cross-reacted 
with rat and mouse orthologs (IC50 = 6.0 nM and IC50= 1.0 nM, respectively) (Figure 28F). DF2593A (tested 
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at 10 M) was selective on a panel of different GPCRs and ion channels (Table 4.) and was also completely 
inactive (% inhibition = 10 ± 3; mean ± SD; three experiments performed in duplicate) in a PGE2 production 
assay.28  
Table 4. 
 
Data are presented as mean (± SD, n = 3) of the % of binding of radioligand after the incubation with DF2593A at the single 
concentration of 10 M. For TRPM8, TRPV1 and TRPV4 experiments, data are presented as IC50 values of three different 
experiments. a The effect of DF2593A was evaluated at 10, 1 and 0.1 uM. DF2593A retains about 1000 fold of selectivity versus M2 
and M3. 
 
Binding experiments carried out on PMN membranes with radiolabelled C5a showed that DF2593A did not 
compete with binding of C5a. Pretreatment of PMN with DF2593A (1 M) did not change C5a affinity for 
C5aR (Kd = 1.8 ± 1 nM and 1.0 ± 0.4 nM in vehicle and DF2593A-treated groups, respectively; n=3/group). In 
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addition, DF2593A did not affect the number of C5aR molecules expressed on the cell membrane (127000 ± 
13000 and 133000 ± 21000 binding sites/cell in vehicle and DF2593A-treated groups, respectively) and did 
not alter C5a binding to C5aR in displacement experiments (Figure 28G and Figure 28H). 
4.2.3 Pharmacokinetic profile of DF2593A 
The pharmacokinetics of DF2593A was investigated in mice after intravenous and oral administration. 
Following oral administration (1 mg/kg) in mice, DF2593A was well absorbed (F = 83%) with a Cmax of 0.1 
M, a tmax of 1.2 h and plasma samples harvested over a period of 12 h, generated free plasma drug 
concentrations in the range 0.016 - 0.004 M, about 4 to 16-fold greater than its in vitro IC50. For brain 
permeation studies, DF2593A was dosed i.v. at 10 mg/kg and the levels of DF2593A were 913 ng/g tissue 
and 673 ng/ml in brain and plasma respectively, at 5 min post dose. At 8 h post dose, significant levels of 
DF2593A were still present in the brain (114 ng/g) and also in the plasma (56 ng/ml). The brain-to-plasma 
ratios of DF 2593A ranged from 1.36 (at 5 min post dose) to 2.04 at 8 h post dose. In parallel, the 
distribution coefficient, logBB, increased from 0.13 (at 5 min) to 0.3 (at 8 h), suggesting good permeation of 
the molecule into the brain. 
4.2.4 Antinociceptive effects of DF2593A in several models of inflammatory pain 
C5a/C5aR interactions mediate carrageenan-induced mechanical hyperalgesia in rodents, suggesting it was 
a reasonable model to evaluate the potential analgesic effect of DF2593A.7In  corroboration, carrageenan-
induced inflammatory hyperalgesia is reduced in C5aR-/- mice compared with WT mice (Figure 31 (S4)).  
 
Figure 31. Inflammatory hyperalgesia induced by carrageenin (Cg), but not by PGE2, is reduced in C5a null mice. WT or C5aR-/- mice 
ed. 
Data are shown as mean ± SEM. * P<0.05when compared to wild type group; n=6. 
Consistently with its in vitro potency, oral administration of DF2593A inhibited carrageenan-induced 
mechanical hyperalgesia in a dose-dependent manner, but did not alter the mechanical threshold in naïve 
mice ( Figure 32A Fig. 2A). C5a-induced hyperalgesia was also blocked by DF2593A, supporting the concept 
that DF2593A blocks hyperalgesia by inhibiting the C5aR (Figure 32  Fig. 2B). Neither DF2593A nor C5aR-/- 
deletion affected mechanical hyperalgesia induced by PGE2 injected in the mice paws (Figure 32C and 
Figure 32D). Furthermore, DF2593A did not alter epinephrine-induced hyperalgesia in the mice paws 
( Figure 32Fig. 2C). In an attempt to test the effect of DF2593A against chemical nociception, a writhing test 
induced by zymosan was studied.29 Oral treatment of mice with DF2593A significantly reduced zymosan-
induced writhing response  (Figure 32D). DF2593A had no opioid-like affect in the hot-plate test and did not 
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cause any motor impairment that could have accounted for the analgesic effects observed (Figure 32E and 
F).  
 
Figure 32. Antinociceptive effects of DF2593A on acute inflammatory pain models. (A) Mice were treated orally with vehicle or 
DF2593A (0.25 - 2 
Mice were treated orally with vehicle (saline) or DF2593A (1 mg/Kg), 50 minutes before i.pl injection of C5a (300 ng/paw). (C) Mice 
were treated orally with vehicle (saline) or DF2593A (1 mg/Kg), 50 minutes before i.pl injection of PGE2 (100 ng/paw) or epinephrine 
(300 ng/paw). Mechanical hyperalgesia was evaluated 60 min after stimuli injection. (D) Mice were treated orally with vehicle 
(saline) or DF2593A (1 mg/Kg) 50 minutes before intraperitoneal injection of zymosan (1 mg/cavity). The number of writhing 
response induced by zymosan was evaluated during 20 min n=8. (E) The thermal nociceptive threshold in naïve mice was evaluated 
before and at indicated time after DF2593A treatment (1 mg/kg) using hot-plate test. Morphine (8 mg/kg s.c.) was used as a 
positive control. (F) Naïve mice were treated orally with vehicle or DF2593A (1 mg/Kg) followed at indicated times by evaluation in 
rota-rod test. Diazepam (7.5 mg/kg, s.c) was used as a positive control. Data are shown as mean ± SEM. (n = 6-8 per group). 
*P<0.05 as compared with vehicle-treated animals. 
Treatment with DF2593A or genetic deletion of C5aR (C5aR-/- mice) did not alter carrageenan-induced PMN 
accumulation (Figure 33), in agreement with our previous findings.7  
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Figure 33. Role of C5a in neutrophil migration during carrageenin (Cg)-induced inflammation in mice paw. (A) Effect of DF2593A on 
the Cg-induced increase in paw MPO activity. Mice were treated orally with vehicle (saline) or DF2593A (1 mg/Kg) 50 min before 
mg tissue) was evaluated in the plantar tissue 5 
h after Cg injection (B) WT and C5aR-/- 
neutrophils 104/mg tissue) was evaluated in the plantar tissue 3 h after Cg injection. Data are shown as mean ± SEM. n=6. 
The analgesic effect of DF2593A was then tested in the complete Freund’s adjuvant (CFA)-induced chronic 
inflammatory pain model. Oral pretreatment with DF2593A inhibited CFA-induced mechanical hyperalgesia 
(Figure 34A). Coherently with its plasma levels, the effect of DF2593A was detected at least 6 h after CFA 
injection, but not at 24 h (Figure 34A). We then studied whether the post treatment with DF2593A could 
modify mechanical CFA-induced hyperalgesia and whether the analgesic effect was maintained. As 
reported in Fig. 3B and C, delayed treatment with DF2593A (24 h after CFA injection) reduced CFA-induced 
mechanical and thermal inflammatory hyperalgesia. In a therapeutic setting, treatment with DF2593A 
starting at 24 h after CFA injection and then twice a day for one week reduced mechanical hyperalgesia 
(Figure 34D). Interestingly, the effect of DF2593A was maintained and when DF2593A treatment was 
stopped, mechanical hyperalgesia resumed to basal levels (Figure 34D). There is evidence to suggest that 
C5a contributes to the pathogenesis of rheumatoid arthritis, including arthritic pain.7 30 Therefore, in the 
next step we evaluated the effect of DF2593A in the genesis of articular hyperalgesia in two models of 
arthritis in mice, antigen- and zymosan-induced arthritis. Oral pretreatment with DF2593A effectively 
inhibited articular hyperalgesia in both models (Figure 34E and F). 
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Figure 34. Effects of DF2593A on CFA-induced mechanical and thermal hyperalgesia and arthritic nociception. (A) Mice were treated 
th 
vehicle or DF2593A (1 mg/Kg) 24 h after i.pl injection of CFA (10 μL/paw). (B) Mechanical or (C) thermal nociceptive threshold was 
evaluated 2-24 h after DF2593A treatment. (D) DF2593A (1 mg/kg) or vehicle was given at 24 h after CFA injection and then twice a 
day until 7 days after CFA. Mechanical hyperalgesia was evaluated at 6 h after the first daily dose of DF2593A.  (E, F) Mice were 
pretreated orally with vehicle (saline) or DF2593A (1 mg/Kg) 50 minutes before intraarticular injection of mBSA (30 μg/joint) in 
immunized mice or before intraarticular injection of zymosan (150 μg/joint) in naive mice. Mechanical nociceptive threshold was 
evaluated 6 h after stimuli injection. Data are shown as mean ± SEM. (n = 6 per group).*P<0.05 as compared with vehicle-treated 
animals. 
4.2.5 Antinociceptive effects of DF2593A in the SNI model of neuropathic pain 
As activation of the complement system at the site of nerve injury and in the spinal cord contributes to 
induction and establishment of neuropathic pain,8 31 the effect of DF2593A in the SNI-induced neuropathic 
pain model in mice was evaluated. Oral treatment with DF2593A seven days after surgery clearly reduced 
mechanical hypersensitivity induced by SNI (Figure 35A). The effects of DF2593A persisted at least 6 h after 
treatment and, coherently with the pharmacokinetic profile, a progressive loss of antinociceptive effect 
was observed after 24 h (Figure 35A). Confirming the involvement of C5aR in the genesis of neuropathic 
pain, mechanical hypersensitivity 7 days after SNI was also reduced in C5aR-/- mice when compared with 
WT mice (Fig. 4B). Furthermore, treatment of C5aR-/- mice with DF2593A did not produce any further 
antinociceptive effect when compared with C5aR-/- mice treated with vehicle (Figure 35B). The mechanical 
nociceptive threshold of C5aR-/- naïve mice did not differ from WT mice (Mechanical nociceptive threshold 
of naïve WT mice: 7.2 ± 0.6 g and naïve C5aR-/- mice: 6.8 ± 0.1 g). 
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In a therapeutic setting, DF2593A was given twice a day from day 7 to day 14 after surgery and mechanical 
hypersensitivity measured 6 h after the first daily dose. As seen in Figure 35C, the effects of DF2593A were 
immediate and maintained over the observation period. Mechanical hypersensitivity returned to the same 
level of SNI control group two days after the suspension of the DF2593A treatment (Figure 35C).  
 
Figure 35. Antinociceptive effects of DF2593A in the spared nerve injury model of neuropathic pain. (A) DF2593A (1 mg/kg) or 
vehicle (saline) were given orally 7 days after SNI surgery in mice. Mechanical hypersensitivity was evaluated from 2 to 24 h after 
oral administration of DF2593A. (B) Mechanical hypersensitivity was evaluated 7 days after SNI surgery in WT and C5aR-/- mice 
(time 0) followed by the treatment with vehicle or DF2593A (1 mg/kg). Mechanical hypersensitivity was then evaluated 2-24 h after 
DF2593A or vehicle treatment.  (C) DF2593A (1 mg/kg per dose) or vehicle (saline) were given at day 7 and then twice a day until 14 
days after SNI. Mechanical hypersensitivity was evaluated at 6 h after the first daily dose of DF2593A during one week. Data are 
shown as mean ± SEM. (n = 6 per group). *P <0.05 as compared with vehicle-treated animals. 
4.3 DISCUSSION 
This paper reports the molecular conception, synthesis and characterization of the preclinical candidate 
DF2593A that shows potent and selective inhibitory effect on the C5a-induced PMN migration and optimal 
pharmacokinetic and pharmacological profile in a panel of relevant inflammatory and neuropathic pain 
experimental models.  
In recent years, allosteric modulation of GPCRs has been proposed as a promising new paradigm for the 
design of potent and selective drugs with improved drug-like properties, finely modulating the receptor 
function. There is emerging evidence to suggest that, despite marked differences between the natural 
ligands, GPCRs share common activation mechanisms involving specific microswitches that regulate 
interhelical movements which offer unprecedented opportunities for the rational drug design of novel 
allosteric modulators. In this context, modeling and crystallographic studies of the GPCRs have identified in 
the TM region of GPCRs a major pocket and a minor pocket which has been proposed as a “triggering 
domain” not involved in natural ligand binding but crucial for the fine tuning of the global receptor 
activation process.17 Previous studies elucidated that reparixin, an allosteric inhibitor of CXCL8 receptors, 
binds CXCR1 within the minor pocket locking the receptor in the inactive state by interhelical polar 
interactions with residues of TM1, TM3, TM6 and TM7.19 
Guided by the hypothesis that this minor pocket may represent a functionally conserved site across the 
GPCR family, homology modeling studies and molecular dynamics simulations of C5aR were carried out. 
Despite the low overall identity between C5aR and chemokine receptors, sequence analysis revealed that 
the three key residues identified for reparixin and CXCR1 are conserved in C5aR.22 Taking advantage of the 
structural diversity of other residues surrounding the minor pocket in C5aR and CXCR1, rational design was 
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addressed by targeting a specific pattern of interactions to retain full selectivity to C5aR. Extensive site-
directed mutagenesis studies in C5aR confirmed that this region is not directly involved in ligand receptor 
binding or critical for receptor activation and function. This finding nicely fits with the most accredited 
model of C5a/C5aR interaction 31 according to which the flexible C terminal of C5a is implicated in the 
recognition of a domain distinct from the allosteric pocket and delimited mainly by Arg2065.42, TM4, and 
the second extracellular loop. Nevertheless our studies clearly demonstrated that specific ligands at this 
minor but conserved site are potent inhibitors of the C5a-induced chemotaxis acting as neutral non-
competitive allosteric inhibitors. Interestingly, as the key residues involved are well conserved in both rat 
and mouse orthologs, the above results pave the way for the rational design of allosteric C5aR inhibitors 
with most favorable cross-species reactivity characteristics.  
Previous studies have characterized the role of the C5a/C5aR signaling in the genesis of inflammatory and 
neuropathic pain.7 8 Neuropathic pain is an important and relatively common clinical condition and 
available therapies are only partially effective. Among the events implicated in the genesis of neuropathic 
pain, neuroimmune interactions, including spinal activation of glial cells and the production of pro-
inflammatory mediators, seem to be important for pain amplification. It was shown that expression of 
common genes, including the complement system genes, occurred in three different models of peripheral 
neuropathy.8 These findings are in agreement with the inhibition of complement activation by the 
intrathecal administration of a soluble human complement receptor type 1 (sCR1), which prevented the 
activation of C3 and C5 convertases and reduced mechanical allodynia in various neuropathic pain 
models.31 Additionally, C6 deficient rats still presented nerve injury-induced mechanical allodynia, 
suggesting that  membrane attack complex assembling is not necessary for the induction of neuropathic 
pain states.8 Accordingly, the nociceptive activity of the complement system appears to be strongly 
dependent on the C5a/C5aR interaction. Indeed, after nerve injury, expression of C5aR and C5 in the 
microglial cells of the spinal cord increased and C5 deficient mice or intrathecal treatment with the classical 
antagonist PMX-53, ameliorated nerve injury-induced allodynia.8 Altogether, this preclinical evidence 
strongly supports the hypothesis that C5aR is an interesting target for neuropathic pain control.  
The precise cellular site of action of DF2593A in the nociceptive system is not fully understood. Considering 
the aforementioned evidence of a role of C5a in the CNS, the efficacy of DF2593A in the SNI model may 
arise in part from its permeability to the blood-brain barrier. However, activation of the complement 
system in the periphery, at the level of nerve injury and DRG, could also contribute to the genesis of 
neuropathic pain.31 32 In the periphery, DF2593A could disrupt the activation and the recruitment of 
leukocytes, thus attenuating the direct sensitization of the primary nociceptive neurons expressing C5aR.33 
Importantly, DF2593A was effective even when given one week after SNI, and nociceptive hypersensitivity 
returned to basal values when the DF2593A treatment was halted. These results clearly confirm the 
therapeutic potential of DF2593A and show that continuous activation of the C5aR is relevant for induction 
and maintenance of nociceptive hypersensitivity in the SNI model. 
In the inflammatory pain models, the actions of C5a appeared to be sequential to PMN activation, which 
are recruited into the inflammatory site in response to chemokines and lipid mediators.7 Recent evidence 
showed that C5aR is expressed in primary nociceptive neurons and that C5a could directly sensitize these 
fibers.12 13 Our studies showed that DF2593A blocked carrageenan and C5a-dependent mechanical 
hyperalgesia in vivo without sedative or central opioid-like effects. Interestingly, DF2593A was also 
effective in a model of chronic inflammatory pain and in two models of inflammatory arthritic disease even 
when administered 24 h after the induction of inflammation, sustaining the therapeutic potential of 
DF2593A and suggesting that C5a is continuously produced and participates in the events leading to 
maintenance of chronic inflammatory pain. On the other hand, DF2593A did not affect mechanical 
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hyperalgesia induced by PGE2 or epinephrine, which directly cause sensitization of primary nociceptive 
neurons.6 Therefore, the analgesic effects of DF2593A cannot be ascribed to a non-specific action and is 
related to its ability to block C5a/C5aR signaling, presumably on both PMN and nociceptive neurons. Finally, 
it is important to point out that the results obtained with C5aR-/- mice strongly provide target 
validation/specificity for the effects of DF2593A.  
Our findings underline the functional relevance of the minor pocket in GPCR that, though not directly 
involved in natural ligand binding, cooperates with the fine tuning of the receptor activation process and 
represents an attractive structural determinant for the rational design of innovative therapeutic 
compounds. Our pharmacological results not only provide further support to the role of C5a/C5aR signaling 
in the generation and maintenance of neuropathic pain but also demonstrated that DF2593A represents an 
innovative non competitive allosteric drug candidate to control pain in multiple therapeutic indications.  
4.4 MATERIALS AND METHODS  
4.4.1 Molecular modeling.  
The TM domains of CXCR1, CXCR2 and C5aR were identified by sequence alignments with rhodopsin 
structure by using the MUSCLE software. The C5aR model was refined and compared with CCR5 (pdb code: 
4MBS) and further optimized by verifying the GPCR TM-fingerprints alignment.20 21 The C5aR TM bundle 
was assembled and refined as described in the SI and the final C5aR structure was used to dock DF2593A 
using LiGen. 
4.4.2 Cells and migration assay.  
PMN and L1.2 cells migration was evaluated using a 48-well micro-chemotaxis chamber as previously 
described.19  
4.4.3 Mechanical nociceptive paw test in mice.  
Mechanical hyperalgesia was tested in C57BL/6, BALB/C mice and in C5a-receptor-deficient mice (C5aR-/-) 
using the electronic von Frey test as previously reported.6  
4.4.4 SNI-induced neuropathic pain-like behavior.  
The SNI procedure comprised an axotomy and ligation of the tibial and common peroneal nerves leaving 
the sural nerve intact.34 
4.4.5 Data analyses and statistics.  
For in vivo experiments, results are presented as mean ± SEM. The differences among the groups were 
compared by ANOVA (one-way) followed by Bonferroni's post hoc test. The level of significance was set at 
P<0.05.  
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5 MOLECULAR ASSEMBLIES: MULTI-DIMENSIONAL HIERARCHICAL SCAFFOLD 
ANALYSIS 
5.1 INTRODUCTION 
The identification of common structural moieties and chemical features present in the large and diverse 
sets of compounds identified in high-throughput screening (HTS) campaigns is a long standing and unsolved 
critical point in the hit prioritization phase and in the definition of the chemical follow-up strategy. The 
establishment of effective preliminary structure activity relationships (SAR) is the first fundamental step 
that affects the probability of success of the entire lead discovery process. Different approaches have been 
developed to classify hundreds of thousands of compound hit from HTS campaigns and to search up to 
millions of discarded compounds looking for false negatives or latent hits. 
In our experience those approaches leading to results that can be easily interpreted by a medicinal 
chemistry perspective are the most effective. The reason is that the final goal of the analysis is to identify 
the most promising chemical series to be prioritized on the basis of their synthetic feasibility and novelty. 
Frequently used descriptors often generate good computational models which are, however, not always 
readily interpretable or simple to explain. Furthermore, they often generate multi chemotype ensembles 
that do not help answer the final question: “Which chemical series shall I develop?” 
A chemical scaffold also referred to as ‘chemotype’ or ‘Markush structure’, can be defined as the common 
structure characterizing a group of molecules. Molecules sharing the same scaffold are likely to have a 
similar synthetic pathway as an extension of the concept of molecular template in combinatorial chemistry1. 
Once a scaffold is defined, SARs can be developed by means of the analysis of the effects of the substitution 
patterns. 
Since the first publication of Bemis et al.2, which introduced a systematic analysis of drugs according to 
their scaffold/framework representation, the interest in the approach based on this representation has 
increased continuously and it is now a well-established method which flanks molecular descriptors, 
molecular fingerprints and graphs. Advantages of the approach are: 1) outcomes are both simple to 
interpret and medicinal chemistry-oriented; 2) some of the most significant features of the graph-based 
approaches3 are combined with some others of the molecular fingerprint and the maximum common 
substructure methods. 
The introduction in 2005, by Wilkens et al.4, of hierarchies based on several kinds of scaffold 
deconstructions represented a milestone in the development of  scaffold-based approaches. 
In 2007 Schuffenhauer et al5. demonstrated the potentiality of combining the scaffold-based approach with 
ad hoc graphical representations through the “Scaffold Tree” algorithm and  visualization tool; in that work,  
a rule-based ring disassembly was also introduced. Since then, other decomposition and visualization tools 
have been developed, such as Scaffold Hunter in 20096 and Scaffold Explorer in 20107.  
In 2008 Gianti and Sartori8 proposed an alternative procedure to address scaffold decoration, pruning and 
fragmentation as a workflow for the identification of “privileged fragments”. 
Agrofiatis et al.7, in 2010, demonstrated that the inclusion of relevant side chains and functional groups in 
the scaffold representation could greatly enhance the derivation of robust SAR, thus indicating that the 
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explicit consideration of the most significant molecular features overcomes the limits associated with the 
definition of “a priori” pruning rules. In the same year, our group  presented the Molecular Assemblies 
(MA) approach at 18th European Symposium on Quantitative Structure-Activity Relationships (QSAR)9.  
In 2011, Varin et al.10 proposed an extended version of the previously developed Scaffold Tree and 
demonstrated that rule-based approaches in fragmentation are less useful and flexible than  unbiased ones.  
Lipkus11 introduced hierarchies between different abstraction levels and, finally,  different hierarchical 
scaffold decomposition and abstraction approaches were proposed by many authors such as Vogt et al.12 
and Hu et al.13 
In theory, it is possible to define an arbitrary number of scaffold's representations based on levels of 
abstraction and pruning rules. Figure 36 shows an example applied to the well-known COX-2 inhibitor 
celecoxib14. 
 
Figure 36. Possible scaffold definitions for celecoxib 
A further generalization of Figure 36a obtained by removing the ring size and the internal chain length is 
out of the generally accepted boundaries of what is considered to be a molecular scaffold analysis. It could 
instead represent the starting point for the molecular graph analysis15 an alternative, and somehow 
complementary strategy for data analysis, clustering16, scaffold hopping17, and similarity search18.  
Based on our experience of biological data analysis, the main limitation of these implementations (Figure 
36a to Figure 36e) is that a single representation of the scaffold is not sufficient to effectively capture the 
relationship between the biological activity and the chemical structure of a heterogeneous ensemble of 
molecules. Actually, most of the methods described so far are based on one unique scaffold abstraction, 
such as those depicted in Figure 36c and Figure 36d. These representations are highly effective in 
congeneric series but quite poor in describing multi scaffold libraries. The problem is that it is not possible 
to define a priori the best representation of a molecule because it depends mainly on the biological context 
and on the other nearest-neighbors belonging to the screened library. This is particularly true in HTS 
campaign, in which data analysis and the design of follow-up libraries still lack a general and flexible 
methodology to derive structural information out of molecular collections and, where possible, to correlate 
them with real or predicted biological activities. SAR visualization, in other words, still lacks  generality 
(abstraction level) without limiting the need for precise structural information when needed, even if many 
remarkable approaches have been proposed19. 
In this paper a novel tool named Molecular Assemblies is proposed to overcome restrictions in the use of 
scaffold analysis based on a single predefined set of rules when diverse libraries are used. We demonstrate 
here that these limitations affect hit prioritization together with scaffold hopping and SAR expansion in lead 
optimization settings. 
1a 1b 1c 1d 1e 1f
(celecoxib)
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5.2 MOLECULAR ASSEMBLIES. 
 In HTS campaigns the hits are usually molecules with activity in the micromolar range20 and in this range of 
concentration the recognition of the interaction sites are in general ruled by shape and molecular 
electrostatics more than by more specific and directional interactions. For this reason, it is quite common, 
for instance, that saturated and aromatic rings show the same activity or that different kinds of chains and 
functional groups could be exchanged in the molecule while retaining the same level of biological activity. 
In this scenario, it is not surprising that scaffold representation like Figure 36a, Figure 36b, and Figure 36c 
perform generally better than the others in the identification of relevant chemotypes, as they are able to 
cluster together different molecular species which behave similarly in the biological context of the HTS 
campaign 
We intend to demonstrate that representation at a high level of abstraction, like Figure 36a-c, is better 
suited also to cluster molecules characterized at a nanomolar range of activity. As an example,  we have 
interrogated the Integrity™ database searching for COX-2 inhibitors.  
Integrity™ (query date: 2012.11.02) collected 1912 Cyclooxygenase-2 Inhibitors, 457 of them in preclinical 
development or a higher phase. If we use representation Figure 36a, as depicted in Figure 37below, a 
subset of 128 molecules was identified. These 128 molecules correspond to 51 different scaffolds if 
representation Figure 36d (rings and chains connecting rings) is used 
 
Figure 37. MDL substructure query, of the COX-2 inhibitor common moiety (any atoms and any bonds). 
Interestingly, representation Figure 36 includes and  clusters together well known marketed drugs such as 
valdecoxib, celecoxib and carecoxib as well as many others leads and experimental drugs. Whereas in 
Figure 38. Scaffold representations of 10 of the most diverse cyclooxygenase-2 inhibitors show ten of the 
most diverse cyclooxygenase-2 scaffold substructures (according to the Tanimoto index calculated by 
ECFP6 fingerprint) obtained by using representation Figure 36d.  
 
Figure 38. Scaffold representations of 10 of the most diverse cyclooxygenase-2 inhibitors 
Inspection of Figure 38, however, suggests another important consideration: 26 out of 51 scaffolds have 
one or more additional rings; this means that even if the highest level of abstraction is used 
(Representation Figure 36a) more than 50% of the structural scaffolds’ information would be lost. If the 
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entire set is considered, also including molecules in initial biological testing phase, the ratio increases to 
130 over 188 scaffolds.  
Attempts to extend the structural information coverage has been presented in the past, for example by 
rule-based decompositions proposed by Schuffenhauer et al21, but, as shown in Figure 39, it is difficult to 
define a set of rules that maintains a general consistency with the SARs;  
 
Figure 39. Rule-based scaffold’s decompositions are not always able to identify the most useful representation of the molecules. In 
green a tentative rule-based decomposition is represented; in this case the reasonable hypothesis that phenyl rings are less relevant 
than heterocyclic ones leads to sub-scaffolds lacking the COX2 moiety. 
If representation Figure 36c (atom type but not bond type retained) is used and a scaffold-based cluster 
analysis is performed on the subset of 128 COX-2 inhibitors having only three rings, the outcome is 25 
unrelated clusters. In an ideal example of a screening collection of 100,000 molecules, if the 128 active 
COX-2 inhibitors are identified as hits, the useful information is spread and hidden in more than 500 other 
unrelated clusters of molecules. On the other hand, if representation Figure 36a is used, all the active 
molecules collapse to a single cluster which probably includes many other inactive molecules. This will be 
the case especially when scaffolds deconstructions and ring disassembly are implemented; a case in which 
the enrichment factor associated to the cluster should be low, thus resulting in a de-prioritization with 
respect to less relevant ones. 
It might finally be assumed that representation Figure 36b (no atom type but bond order retained) allows a 
more effective clustering of the important information. In practice, however, it could be demonstrated that 
the analysis strongly depends on the nature of the dataset, and it is very hard not to bias the analysis if a 
priori suboptimal representation is used. 
Thus, we can conclude from this initial example that none of the scaffold representations of Figure 36 is 
able alone to capture the complexity of the entire ensemble of molecules. 
The Drug Discovery Platform at Dompé has started a program to implement cheminformatics tools able to 
increase the communication between medicinal chemists and cheminformatics to effectively share SAR 
information and hypotheses, and to plan synthetic strategies for future ad-hoc collections, without the 
limitations arising from the current technical boundaries of literature methods. As a result of these efforts, 
we have  implemented a tool able to cluster molecules by means of an abstraction method which is more 
medicinal chemist oriented than those based on a cheminformatics SMARTS rule22 or fingerprint similarity. 
This aim has been reached by developing a  suite of proprietary tools based on Java Programming language 
and Pipeline Pilot scripting and this suite, currently employed in our HTS routine data analysis and library 
design, has been tested by performing a series of experiments hereafter described.  
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5.3 MATERIALS AND METHODS 
5.3.1 Algorithms 
Based on the experience accumulated over years of HTS data analysis and design of follow up libraries, we 
developed the MA toolkit for fast and effective analysis of heterogeneous libraries. Now, we briefly 
describe the set of rules and the pruning methods so far implemented. 
 
Figure 40. Representation of the nine levels of structure decomposition 
As a starting point, we used the widely accepted scaffold abstraction concept (here called Basic Scaffold), 
which, in its simplest representation, is generated by a simple pruning rule, the removal of all side chains 
and terminal atoms. As a side chain definition is not always straightforward, we have identified a set of nine 
MA at different abstraction levels, as shown in the Figure 40. Two sets of pruning rules able to define a 
multidimensional hierarchy have been thus defined. The first rule, which increases chemical abstraction, 
removes the atom type label (thus generating a Framework) then the bond order (thus generating a 
Wireframe). The second set of rules is based however, on an increased level of structural information with 
respect to the basic scaffold: as a first step terminal atoms with bond order greater than one are 
maintained (“Decorated Scaffold”), and, as second step, the longest atom chain, considering also 
substitutions, is retained but all terminal non-carbon atoms belonging to side chains are pruned iteratively 
(“Augmented Scaffold”).  
One general limitation of scaffold based techniques4, 6, 21 is that by  definition, molecules sharing only 
partially the same scaffold belongs to distinct clusters. 
To overcome this limitation, we have implemented an unbiased fragmentation scheme that can be applied 
to all nine MA, Figure 41 depicts an example of fragmentation based on an exhaustive and progressive 
elimination of all the chains from the scaffold.  
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Figure 41. Representation of the hierarchical decomposition of a molecule by the exhaustive and progressive elimination of all the 
chains from the scaffold. 
Unbiased ring disassembly has been also implemented; the methodology for ring decomposition involves 
the removal of all fused rings, allowing them to open in fragments. The procedure is exemplified in Figure 
42. 
 
Figure 42. Representation of the hierarchical decomposition of a molecule by the exhaustive and progressive elimination of all fused 
rings from the scaffold. 
For the sake of consistency, we have also introduced a rule to remove internal rings as shown in Figure 43. 
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Figure 43. Representation of the hierarchical decomposition of a molecule by the exhaustive and progressive elimination of all 
internal rings from the scaffold 
These fragmentations and deconstructions introduce other hierarchies, meaning that each fragment of the 
original scaffold is related to all the other representations in a multi-dimensional space.  
Because of this multi-dimensional hierarchical scaffold analysis the entire MA produced are highly 
interconnected and it is possible to move from one to another following SARs. To clarify this concept in 
Figure 44 is reported an example of how it is possible to combine hierarchies to cluster together molecules 
with different scaffolds.  
 
Figure 44. 
In the application paragraph a procedure able to generate hierarchies of combinations of representations 
by the use of network representation is reported 
In Table 5 the output of ring disassembly component is reported; the collected information allows 
displaying and analyzing results as hierarchies.  
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Table 5. Components’ output of ring disassembly  
Frag 
id 
Parent 
id 
N. 
of 
frag. 
Smiles String Parent Smiles string frequency 
0 -1 9 C1SCn2cccc2c3ccccc13   1 
1 0 9 c1ccc(cc1)c2ccc[nH]2 C1SCn2cccc2c3ccccc13 1 
2 0 9 C1SCc2ccccc2C=N1 C1SCn2cccc2c3ccccc13 1 
3 2 9 c1ccccc1 C1SCc2ccccc2C=N1 1 
4 2 9 C1SCN=CC=C1 C1SCc2ccccc2C=N1 2 
5 0 9 C1SCn2cccc2C=C1 C1SCn2cccc2c3ccccc13 1 
6 5 9 c1cc[nH]c1 C1SCn2cccc2C=C1 1 
7 5 9 C1SCN=CC=C1 C1SCn2cccc2C=C1 2 
8 0 9 c1ccc(cc1)CSCn2cccc2 C1SCn2cccc2c3ccccc13 1 
The “Frag ID” tag indexes the number of fragments starting from 0 for the parent Molecular Assembly chosen, “Parent frag. Id” 
establishes the parent-child hierarchy (-1 indicates no parent). The “Number of frag.” is the total number of fragments obtained; 
the SMILES and Parent SMILES strings are respectively the fragment and its parent SMILES strings. The “Frequency” is the 
occurrence of each fragment in the decomposition. 
In our experience, this set of MA and related fragments is able to capture most of the structure activity 
information coming from HTS campaigns, and it is useful for other applications, as described in the next 
paragraph. Especially in case of screening of chemically diverse libraries, the combination of fragments, 
framework and wireframe MA is able to identify relevant chemical moieties in an efficient manner, 
clustering together many scaffolds with similar shapes despite for example different dispositions of hetero 
atoms or  small differences in bond order. At the moment this is not possible with other known 
methodologies, like the widely accepted Maximum Common Substructure (MCS).23 An interesting 
exploitation of this concept will be found in the  paragraph on applications. 
5.4 APPLICATIONS 
5.4.1 Compound Clustering & Database Indexing 
One of the most critical tasks in the design of large diverse libraries is the mapping of chemical space. 
Selection of a representative subset of the desired chemical space is generally addressed by the 
identification of a set of meaningful descriptors24, a similarity metric for determining the pairwise 
comparison of molecular structures25, and a clustering algorithm for grouping structures according to the 
calculated pairwise similarity values26. Many papers compare and analyze clustering algorithms27, and many 
clustering techniques are able to address the task for groups of 105 to 107 compounds. The achievement of 
chemical consistency within the generated clusters from the point of view of the identification of relevant 
chemical series is much more difficult. The generation of groupings that can be considered as “series” in a 
medicinal chemist’s perception should be seen as an important asset of the scaffold based techniques. 
Indeed, the clusters generated by currently available approaches tend to contain an elevated number of 
scaffolds and this makes it difficult to select chemical series for follow-up activities, although some 
corrections have been applied to overcome this problem, for example by means of Maximum Overlapping 
Set (MOS)28. For scaffold-based clustering techniques no similarity indices or calculated pairwise similarities 
are necessary, as  the scaffold structure represents itself the similarity index and the aggregation rule, so 
that each molecule belongs to its own cluster regardless of the nature of the neighbors. In this respect, the 
approach can be defined as a “Natural Clustering” (NC) approach. Another important feature is that no bias, 
like the average number of molecules per group or the expected number of scaffolds, has to be introduced. 
This is very useful when some over-represented scaffolds may drive the analysis. The possibility introduced 
Development and Validation Of In Silico Tools For Efficient Library Design and Data Analysis  
in High Throughput Screening Campaigns 
Chapter 5: Molecular Assemblies: Multi-Dimensional Hierarchical Scaffold Analysis 
 
 
70 
 
by Molecular Assembles to perform hierarchical clustering extends the potentialities of scaffold-based 
clustering. 
NC makes relational databases ideal for chemical graph-based compound clustering applications. A 
compound’s cluster membership is an objective property as it does not depend on the chemical structure 
of the other cluster members, and, once the scaffold abstraction is defined, there is no more need to re-
cluster the whole library. By organizing molecules in the database by means of clustered SQL indices (based 
on the MA), it is possible to dramatically reduce the time required for substructure searches, as reported by 
Wilkens et al.29 and Masciocchi et al.30. In our implementation, due to the higher abstraction of the 
frameworks and wireframes, it is also possible to further speed up substructure searches using these 
representations as a wild character-like approach such as “any atom” or “any bond”. Interestingly, MA are 
per se searchable molecular representations, and this allows for the possibility of defining local similarities 
in substructure searches space. For example, the scaffold of the target molecule could be searched with 
either a lower or higher similarity to the reference template. Besides that, it is also possible to constrain the 
local diversity of the scaffold by requiring, for example, a specific hydrogen bond acceptor within the 
scaffold, or a specific LogP range. 
5.4.2 MA as fingerprints 
Another intriguing aspect is that  it is possible to use the complete ensemble of MA as structural 
fingerprints31 with a minimal number of features. This property makes Tanimoto similarity searches17 very 
fast and not particularly critical in disk occupation when stored in a database. One possible intrinsic 
limitation is, however, due to the under estimation of the side chain contribution to the global similarity of 
the reference molecule with the target ones. On the other hand, our fingerprinting implementation is very 
useful when it is necessary to identify the most diverse set of compounds, based on a scaffold metrics or 
when the goal is to find different molecules with a high degree of similarity in terms of scaffold. 
To generate the set of fingerprints encoded as signed integers we used the hash function, as implemented 
in Pipeline Pilot, of the SMILES representation of the MA, as described in Table 6. 
Table 6. Output properties of the Molecular Assemblies Fingerprint component. 
Molecule Number 
of 
fragments 
Fragment 
SMILES 
Frag. 
Freq. 
MAFP_DS 
 
9 C1SCn2cccc2C=C1 1 1809490360 
c1ccccc1 1 -88666468 
C1SCc2ccccc2C=N1 1 227018873 
c1cc[nH]c1 1 471236740 
c1ccc(cc1)c2ccc[nH]2 1 286785889 
C1SCN=CC=C1 2 -
2045419586 
C1SCn2cccc2c3ccccc13 1 1411062085 
c1ccc(cc1)CSCn2cccc2 1 -
1689663450 
 
In analogy to circular fingerprints32, where it is possible to use different metrics to generate the fragments33, 
it is possible to select scaffolds, frameworks or wireframes as descriptors of the molecule and then to 
generate a corresponding descriptor’s set using fragments and ring disassembly. It is possible to apply the 
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same procedure (hashing the smiles of the fragment structures as the example reported in figure 2) to our 
nine representations to calculate MAFP_XX fingerprints from Augmented Scaffold, MAFP_AS, to Basic 
Wireframe, MAFP_BW.  
As a test case, the MA algorithms were applied to a set of 10 well known commercial libraries. All the 
collections were standardized to hold consistency in protonation states and tautomeric forms (based on 
"Canonicalization and Enumeration of Tautomers", Sayle and Delany, EuroMUG99, 28-29 October 1999, 
Cambridge, UK.). Chemical group representations such as nitro groups and salts were removed. Using the 
standardized structures, internal duplicates in each catalogue were removed, and the  Oprea’s lead likeness 
filter was applied34 thus ending up with a global set of 4.43 million compounds. 
Table 7 reports unique structures calculated for each supplier by using the six most relevant 
representations. From the results it is possible to have a quick view of the chemical space covered by 
suppliers versus the total number of compounds (complete version of table 3 can be found in the 
supporting information). This approach makes it very easy to explore scaffold diversity in a library, to 
compare two libraries, to identify collections with unique or rare scaffolds or to find molecules with the 
same scaffold or sub scaffold in other collections. Moreover, it is also remarkable that these comparisons 
take just a few minutes to run more than 4 million compounds.   
Table 7. For the most commonly used MA representations of each supplier  the number of unique scaffolds 
are reported. 
Vendors BS BF BW DS DF DW 
Alinda 17404 7129 2655 18647 10498 6497 
Ambinter 323636 97864 24853 356027 173682 92904 
Asinex 56104 23953 8581 59964 33660 20945 
Enamine 245620 70394 17251 267872 131223 69701 
IBS
a
 37160 17011 5772 39310 22908 14727 
LC
b
 34143 15279 5378 35387 21321 13840 
Princeton
c
 19423 8950 3074 20873 12601 7850 
Tim Tec 49896 19755 5821 54371 29297 16538 
Uorsy 71034 25934 8959 76280 43495 26529 
Vitas-M 61114 25023 7459 65767 36364 21529 
BS: basic scaffold, DS: decorated scaffold, BW: basic wireframe, DW: decorated wireframe, BF: basic framework, DF: decorated 
framework, a) InterBioScreen, b) Life Chemicals, c) Princeton Biomolecular Research 
 
Another interesting example is the comparison of the chemical similarity among all suppliers by an 
extended connectivity fingerprints33b such as ECFP6 and MA. The results are reported in Table 8 and Table 9. 
Asymmetric matrices in the two tables account for the percentage of identity in unique ECFP6 fingerprints 
and unique MAFP_DS, respectively. The latter case is actually the amount of decorated scaffolds (DS) in 
common with respect to the total number of DS in a library. The matrices are asymmetric because of the 
different number of DS in each library. 
As  can be seen directly from color code mapping in Table 8, the average similarity (ECFP6 average 
similarity: 23.4%) is less than that shown in the Table 9 (MAFP_DS average similarity: 36.6%). It is 
reasonable to say that scaffold diversity is smaller than molecule diversity. For example, comparing Alinda 
and Ambinter catalogues according to ECFP6, the first has 9.8% of the diversity of the second catalogue 
which itself has 14.8% of the diversity of the first one. A fingerprint comparison suggests that the two 
libraries are mutually diverse, a dramatic change in the results using the DS metrics can be observed: 
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Ambinter contains  95.9% of the Alinda collection while this latter contains  5% of the Ambinter DSs. 
Combining the information it is possible to say that the Ambinter contains most of the Alinda scaffolds 
which, in turn, show a different decoration pattern,. Therefore, depending on the scope of analysis, it is 
possible to focus on  4.1% of its novel scaffolds or to focus on the common scaffolds in order to increase 
their diversity. Another interesting comparison: IBS and Life Chemicals (LC) catalogues collect almost the 
same number of lead-like compounds (IBS: 161317 and LC: 140346) and DSs (IBS: 37160 and LC: 34143). 
Nevertheless, the two catalogues are very different in both metrics, showing less than 20% of scaffolds and 
15% of fingerprints overlap. Therefore, combining the two libraries would enhance the global diversity 
since they clearly map distinct parts of the chemical space. 
Finally, another interesting comparison can be made. Enamine and Uorsy libraries show a fingerprint 
similarity  of around  50% but Uorsy contains 12% of the Enamine DS which in turn contains 41.8% of Uorsy 
DS. In this case the two libraries are highly complementary in DS. Combined with the high similarity in 
decoration pattern, this feature can be exploited, for example, in scaffold hopping approaches. 
Table 8. Similarity matrix of 10 chemical libraries of screening compounds based in ECFP6 fingerprint. 
 
The table reports the percentage of similarity aongst 10 chemical collections of commercially available 
compounds as from ECFP6 fingerprint analysis. For sake of clarity, a numeric code has been added to each 
supplier’s name. The color code ranges from red (0%) to green (100%). 
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Table 9. Similarity matrix of 10 chemical libraries of screening compounds based in DS fingerprint 
 
The table contains the percentage of the similarity among a selection of chemical collections of 
commercially available compounds using DS. A numeric code has been added to each supplier’s name for 
clarity. The color code ranges from red (0%) to green (100%). 
If large chemical collections have to be compared, the proposed approach can be considered 
complementary to others reported in literature35. To highlight differences between the two descriptors, the 
principal component analysis of the two similarity matrices is reported in Figure 45. 
 
Figure 45. 
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5.4.3 Molecular Assembly based library design 
Many authors have addressed the challenge of designing both combinatorial36 and diversity-driven libraries 
for specific37 and generic applications38 by focusing on reagents and products.39,37a, 40 
With the aim of designing a library driven by scaffold diversity or follow-up libraries for SAR expansion (as 
from primary HTS data), we propose here two approaches based on the selection of commercially available 
compounds41. 
 Select commercially available compounds seems to be very useful for many reasons, the most relevant 
being: 1- using stock compounds it is possible to rapidly evaluate SAR reducing costs and delivery time41; 2- 
it is not necessary to limit, at an early stage, the chemistry to a few chemotypes based on the primary hits 
scaffolds; 3- as will be described in the next paragraph, the multi-scaffold based procedure allows the 
control of chemotype diversity without dispersion because a significant number of analogues for each 
scaffold is retrieved. Thus the library is made of a collection of diverse chemotypes miniseries. A good 
example of chemical space mapping, according to a hierarchical scaffold metric, is reported by Langdon et 
al.42. where a scaffold tree5 decomposition in combination with Tree Maps43 as visualization tool is shown 
to be an effective way of illustrating both the distribution and structural diversity of chemical scaffolds. 
It is possible to apply MA to the design of follow-up focused libraries for discovery projects. The procedure 
is based on the ability of hierarchies to constrain the shape of molecules and, at the same time, to fine tune 
the diversity and the properties of scaffolds.  
In Figure 46. a schematic representation of this approach is depicted. Once a wireframe is selected, the 
library is created on the derived tree in the basic wireframe > framework > scaffold dimension. 
The core procedure is implemented in our protocol as follows: 
Ring 1: Select a parent wireframe of interest; 
Ring 2: Define a range of values for derived frameworks that have to be represented in the library and 
define the objective function (for example maximize diversity); 
Ring 3: Define a range of values for derived scaffolds, as per selection in the previous step, and define the 
objective function (for example maximize diversity); 
Ring 4: Define a range of values of molecules derived from each scaffold selected in the previous step and 
define the objective functions for  each scaffold library and for the global one (for example maximize 
diversity, drug likeness …) 
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Figure 46. 
The same procedure used to explore a single wireframe could be expanded to an arbitrary number of such. 
The wireframes can have the greatest diversity or be related by fragmentation or ring disassembly rules. 
The latter approach could be successful when used to expand corporate libraries for singletons removal 
strategies and to populate new chemical space. Methodologies to specifically address diversity in the 
scaffold space have  already been described44. We found useful the proposed MAFP, as described in the 
previous section. 
The balance between diversity, to achieve a good coverage of the desired chemical space, and the 
possibility to embed information useful for SAR analysis, is a common issue in the design of a general library. 
Clustering based on similarity index using properties or fingerprint descriptors is very useful in the selection 
of diverse molecules but, depending on the algorithm, it can be difficult to obtain chemotype-oriented 
clusters. 
The concept of chemotype is, of course, questionable but in general it is expected to carry out a set of hits 
able to generate a series that could become the prototype of the Markush structure.45 In turn, the Markush 
structure can be considered conceptually as a scaffold extension (for us a molecular assembly). The reason 
of the frequent inconsistency between clustering in terms of scaffolds is mainly based on marked 
differences in scaffold populations rather than in similarity indexes or descriptors. When the algorithm has 
to cluster thousands of singletons and thousands of molecules belonging to hundreds or even thousands of 
scaffolds, it tends in general to split highly populated scaffolds into different clusters and to aggregate the 
less populated ones. In the reference dataset (4.4 million  lead-like compounds from 10 vendors) 70% of all 
BS have less than 4 analogues and 34% of all BS are singletons. At the same time the most populated BS 
(phenyl ring) have 228752 analogues, and 338 BS having more than 1000 analogues show a mean of 3503 
compounds per cluster (standard deviation is 12752), accounting for 1180769 molecules, that is the 27% of 
the entire set. Summarizing, 61% of the available chemical space is composed by singletons or by 
overpopulated scaffolds; in this scenario, a scaffold normalization technique is needed to retain chemotype 
representation in the library design procedure. 
This problem could be minimized by using the Jarvis-Patrick (JP) clustering method. This method is 
applicable up to medium sized sets (up to 105 compounds) because of the O(N2) dependency in time and 
O(N) in space (where N is the number of items to cluster); as a consequence, a substantial amount of time 
is required if N is large. In other words, if a single processor is used to generate the NxN correlation matrix 
then more than 30 days of calculations are needed to analyze 1 million compounds. Hierarchical 
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(agglomerative) methods show in general a O(N3) dependency in time and O(N2) in space; it could be 
reduced, in the reciprocal nearest neighbor (RNN) version of Ward’s method46 to the same dependency as 
in JP method. 
Using fast clustering methods like MAXMIN47 method of Waldman O(nN) as the one available in Pipeline 
Pilot48 it is possible to handle millions of compounds but it is generally hard to control the sparseness of the 
scaffolds, and some bias like the average number of molecules per scaffold must be introduced. In this 
paper we propose to use methods based on the hierarchy of the MA to generate diverse scaffold-
constrained libraries embedding expected scaffold populations from the beginning with a dependency in 
time of O(N) that may be calculated only once. We calculate the MA during the compounds registration 
procedure without the need for recalculation. 
5.4.4 Network analysis 
One of the most promising applications of MA is in the analysis of large datasets from HTS. Many authors 
proposed effective tools for HTS data analysis.49,50,51,52 Recently, Scaffold Trees have been successfully 
applied to this kind of data5.  
As previously demonstrated by the COX2 inhibitors case example, the higher flexibility of MA is able to 
capture  most of the useful information; it is indeed possible to derive trees in multiple dimensions such as 
wireframe > framework > scaffold or augmented > decorated > basic or wireframe > ring disassembly > 
fragments, and all other possible directions maximizing the information of the dataset. The hierarchical 
representation is very useful, but it does not allow as full a graphical representation of dataset information 
as it could instead being extracted by means of MA in a single visualization. 
To overcome this problem we propose a network representation of the dataset. The MA approach has 
been combined with the network representation in order to generate a more convenient tool for SAR 
evaluation and visualization.53,54,55,56 
This procedure is able to generate a convenient representation of the dataset according to the SAR, and it 
focuses on the assemblies which are relevant to their generation. This reduced representation still encodes 
the hierarchy of the MA, this feature conveniently guides the user from one molecular assembly to another 
in the direction of increasing or decreasing levels of abstraction.  
A procedure aimed at clustering and representing them as a network is now proposed and the core 
procedure is the following: 
 Cluster compounds based on the MA 
 Weighing them by the enrichment factor 
 Generating a connection table for each cluster having at least a molecule in common with 
another one. 
 Weighing the connections according to the number of molecules shared by the clusters. 
Once the data matrix has been generated, it is possible to visualize it by means of many different software 
packages54. Filtering by enrichment factors and by connection weights makes it possible to focus on the 
most relevant information. In Figure 47. a cartoon showing a possible outcome of this analysis is depicted. 
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Figure 47. 
As evidenced by Figure 47. the graphical representation of the data matrix consists of an oriented network, 
where nodes are in general molecular fragments or entire small molecules, and the direction of the edges 
defined by the fragmentation rule starts from the originator fragment and ends up with the corresponding 
fragments. In general, the obtained network is always fully connected, because small fragments 
corresponding for example to the benzene ring are shared by a large group of the original molecules 
contained in the fragmented library. While a quantitative treatment of the obtained network will be 
discussed elsewhere, we anticipate here some qualitative considerations. As a first point, it is reasonable 
that highly connected singletons tend to be small fragments shared by a large number of molecules 
included in the library, whereas low molecular weight singletons, possessing low connectivity, represent 
potential interesting decorations of some specific group of the originator molecules. If this particular group 
is enriched in a specific activity of interest, then the low molecular weight singleton connecting all the 
molecules included in the group could be a pharmacophore.  
As a second point, high molecular weight singletons derived from the fragmentation procedure, which 
connect a cluster of molecules with enriched activity, could represent chemical scaffolds or the “minimal 
chemical entity” conferring the selected activity to the connected cluster. 
As a third point, it is understandable that the significance of the singleton composing the networks may 
change according to the fragmentation rules. While the approach suggested herein consists of a purely 
informatics fragmentation procedure, an alternative method is conceivable, where a network is formed 
only by singletons consisting in reaction intermediates derived from chemical procedures used to produce 
the molecules included in the original library. In other words, the “fragments” included in such a network 
would be the precursors used to synthesize larger molecules. If this is the case, then the pathways 
connecting any two singletons also represent a possible synthetic strategy to be used to attach a specific 
interesting low molecular weight singleton to another representing, for example, a scaffold. 
In our experience connections between chemotypes are not easily identified without the molecular 
assembly’s decomposition. Filtering by enrichment factor and ranking by number of connections of each 
cluster make it possible to focus on the highly connected singletons. These molecules are important 
because they connect different chemotypes without overlapping fragments, giving a better chance to find 
the most relevant parts of active molecules, the fragments that could be exchanged, the bond order and 
the atom type that are relevant for SAR derivation. This approach allows us to start the SAR analysis from 
Development and Validation Of In Silico Tools For Efficient Library Design and Data Analysis  
in High Throughput Screening Campaigns 
Chapter 5: Molecular Assemblies: Multi-Dimensional Hierarchical Scaffold Analysis 
 
 
78 
 
the molecules which are generally underestimated singletons and molecules with small ligand efficacy, 
because these are generally connected to relevant clusters of compound series; in this scenario the 
additional valuable information could be embedded in the SAR of the major hit series to extend and 
connect different series one to another. This approach could be considered an extension of the already 
proposed compound set enrichment10, 57, by implementing a higher level of abstraction it is potentially able 
to identify additional latent hit series58 which are connected with conventional hit series. 
5.5 CONCLUSIONS AND FUTURE DIRECTIONS 
We propose MA as a fast and flexible method for the analysis of the chemical space, library design and SAR 
studies. 
This set of tools could be useful in the management of large compound collections as in the analysis of HTS 
campaign results as well as in focused libraries design. On the other hand, by this kind of data organization, 
the analysis of scaffold-activity relationships is very efficient in the identification of relevant clusters and in 
the connection of different chemotypes by means of biological activity. The limitation in the 
underestimation of the side chain effect can be easily overcome by the joined concurrent of other 
techniques such as molecular matched pairs59 (MMP). In this case the already identified cores (the MA) 
makes MMP equally as or even more efficient60 or consistent61 than other methods. Furthermore, using MA 
with a higher level of abstraction, it is possible to compare effectively SAR behaviors on multiple scaffolds, 
or support scaffold hopping strategies. 
Another interesting application, still in an early phase of evaluation, is the annotation of the library 
according to the categorized drugs by therapeutic areas with the aim of accelerating the identification of 
target-based or disease-based libraries using for example annotated database such as MDDR, CMC or 
WOMBAT62, or public databases63. 
An evolution of MA could be the possibility of defining a set of rules at runtime. It allows the selection of 
the most suitable MA without any previous knowledge or bias. As previously discussed, the definition of a 
fixed set of rules introduces a bias that could be minimized, not completely removed, using our set of nine 
molecular representations. By the introduction of the Generalized Molecular Assemblies (GMA) engine, it is 
possible to change the set of rules iteratively, with many useful procedures like genetic algorithms, 
stochastic approaches or, in some cases, also an exhaustive enumeration of all possible combinations, once 
the optimization function is defined.  
By this approach it is possible to identify the molecular representation able to extract the most relevant 
information contained in the data sets. 
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6 MOLECULAR ASSEMBLIES FOR HTS CHEMICAL LIBRARY DESIGN 
6.1 INTRODUCTION 
A sizeable and properly organized chemical library is a fundamental prerequisite for any High Throughput 
Screening (HTS) project. The quality of a chemical library significantly affects the rate of success of HTS 
campaigns. 
A sizeable and properly organized chemical library is a fundamental prerequisite for any HTS project. The 
quality of a chemical library significantly influences the rate of success of HTS campaigns1,2.The creation of a 
high-quality chemical library is therefore of paramount importance in increasing the odds of finding active 
compounds through HTS. Thus, the creation of new schemes to build structured and diverse compound 
collections is an active research field that continuously evolves in tandem with the needs of increasing 
accuracy and specificity while reducing the total number of compounds to be screened, in order to 
minimize false positive and false negative3. 
The most critical aspects of creating a chemical collection are drug-likeness and analytical properties (i.e., 
identity and purity) of the selected molecules. The number of compounds present in commercial collections 
violating Lipinski rules4 or carrying reactive groups responsible to produce interference with biochemical 
assays is considerably high5.  
Further, other important issues of any chemical library are chemical diversity and chemotype 
representativeness, which are two features that inevitably compete with each another, especially if the 
chemical collection is of limited size. Even when all these characteristics are well balanced within a diverse 
chemical library, however the  chances of false positive results from HTS hits remain relatively high, 
motivating the search for more effective strategies to perform HTS campaigns with higher efficiency.  
To build a chemical collection of approximately 200,000 high quality commercial molecules was the aim of 
the Italian Drug Discovery Network (IDDN) initiative, whose participants are Angelini, Dompé, IEO – 
European Institute of Oncology, IIT – Italian Institute of Technology, Recordati, Rottapharm-Madaus. 
Toward this aim, we first selected a collection of drug-likeness compounds, according to standard criteria 
reported hereafter. We then pursued the objective of creating a diverse compound collection able to 
return a preliminary structure-activity relationship (SAR) from possible HTS hits. This challenge was 
motivated by the central idea that a preliminary SAR from HTS hits could greatly strengthen the hit 
identification process, reducing the rate of false positives and false negatives via the recovery of close 
analogues from congeneric series.   
A significant effort was therefore first devoted to scaffold analysis for the creation of a high quality and 
diverse IDDN chemical library. As a means to optimize scaffold selection and clustering, we here introduce 
the concept of super- and sub- scaffold. Briefly, given any scaffold according to the Molecular Assemblies 
definition, a sub-scaffold is part of the parent scaffold lacking at least one ring system, while a super-
scaffold has at least one ring system more than the parent one (Figure 48). Super- and sub- scaffolds in this 
contest, are the subset of all possible fragments of the Decorated Scaffold representation that correspond 
to the decorated scaffold of another molecule (Figure 50). 
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Figure 48. Schematic Representation of the definition of super-, sub-scaffold and extended scaffold 
The IDDN collection included a minimal number of representatives for each of the selected chemotype 
(scaffold-based). Although limiting chemical diversity, this was an essential step toward the identification of 
preliminary SARs centered on potential HTS hits. Considering that in many cases the first HTS campaign is 
performed with a single replica, one concentration, it is obvious that having singletons increases both the 
false positives and the false negatives ratio. Therefore, a minimum of close analogues would help in 
deciding if positive (or negative) results are true values simply by looking at the whole activity range across 
the cluster. At the same time – evidently – the higher the number of cluster members, the lower the 
“chemical diversity”, no matter how this can be defined. To improve to some extent the cluster 
representativeness without limiting too much the diversity, the relationships between super and sub-
scaffolds have been defined. In this way, it is possible to consider as belonging to the same cluster 
compounds that in accordance with other definitions should fall in different clusters. Furthermore, by 
applying Jarvis-Patrick6 or Ward7 algorithms using Tanimoto8 distance and ECFP_6 descriptors9 as 
implemented in Pipeline Pilot (Accelry),  chemical diversity is measured over the whole structure, thus 
considering side chains as well as ring systems. 
Once all compounds were selected and clustered, we faced the complexity of structuring a chemical library 
for efficient HTS. Our strategy to further facilitate the identification of preliminary SARs from HTS hits was 
to efficiently plate the IDDN collection. To do so, the IDDN library was divided into 5 sets, namely four 
“Diverse” and one  “FollowUp” sets. “Diverse” sets were those collecting centroids and “pseudo-centroids” 
from each cluster, while the FollowUp set contained all the remaining selected compounds organized by 
clusters, as discussed in the forthcoming sections. While each of the four “Diverse” sets contained one 
representative for each cluster, being it the centroid or else the pseudo-centroids, in the “FollowUp” set 
compounds belonging to the same structural clusters were plated together, thus allowing expansion of hits 
identified during screening assays, without the need of “cherry picking”. This last set, containing ~160K 
molecules, was designed to perform the preliminary SAR expansion of hits identified during HTS of the 
Diverse Sets. We thus designed a well-organized scheme that efficiently grouped structurally related 
chemotypes into the same plate. The algorithm is described in detail in the Methods, in brief for each 
vendor and for each cluster, it assigns each compound to a specific well in a specific plate until the plate is 
filled with compounds very similar by definition. This allows the use of each plate as a sort of cartridge 
containing highly enriched groups of compounds similar to those identified as hits in the first HTS step. 
Keeping in mind that the first HTS step is usually performed on the four Diverse Sets, as will be described in 
the Results section, this means that in the first phase four representatives of each cluster are tested, and in 
the second phase from six to about forty compounds of the same cluster are tested, with an average of 
fourteen. This is indeed a key innovative aspect of our scheme for the construction of a diverse chemical 
library for efficient HTS. 
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As a result, a well-organized and diverse chemical collection of about 200,000 compounds was built, with 
the major advantage of allowing a preliminary SAR of potential HTS hits. Remarkably, the final IDDN 
chemical library shows an optimal drug-like profile, highlighting the quality of the included compounds (see 
results section). Theretofore, the proposed scheme for the creation of an organized chemical library could 
in principle be used for larger collections, as well, helping in the creation of other chemical collections for 
efficient HTS campaigns.   
6.2 METHODS 
6.2.1 Initial compounds collection 
We initially collected about 14 million compounds from many vendors.  File cleaning and uniqueness checks 
were performed using standard SD file parsing software (Pipeline Pilot, Accelrys). Vendor files were 
submitted to removal of empty records and standardization of indexing fields, e.g. vendor name and 
catalogue number. Then, an internal identification number (GUID) was assigned to each compound. Other 
common file manipulations were performed, namely chemical groups standardization (e.g. Nitro, Sulfones 
etc), checks for consistency for protective groups (i.e. abbreviations corresponding to chemical structures), 
tautomer fixing, salt removal, and charge neutralization. Once a set of consistent chemical structures was 
obtained, the uniqueness check was performed. Then, the Canonical Smiles10, the InChi and InChiKey were 
generated for each compound. Finally, compounds were filtered to remove undesired molecular structures. 
To do so, several filters were applied, using physico-chemical and topological properties, therefore 
removing unsuitable chemical moieties (PAINS11 and Frequent Hitters12,13,14).  
After this key step, the number of compounds was reduced to 3 million; suppliers were contacted to check 
whose compounds were resulting in 1.1 million available compounds that can be acquired. 
This final set was considered for the additional steps for the IDDN library construction (Figure 49). 
 
Figure 49. Drug-like filters cascade to identify the reference chemical space from the bulk collection of vendor's compounds 
6.2.2 Compound clusterization 
To build the final set of compounds (about 200K), we introduced a clusterization procedure to maximize 
the diversity among classes of compounds, using a novel scaffold-based metric called Molecular Assemblies 
(see chapter 5). 
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Taking into account one ring more or one ring less of the Decorated Scaffold, as a sub set of the Molecular 
Assemblies descriptor this reduced representation is still a hierarchical scaffold metrics. This useful 
representation allows us to consider the additional ring as a substituent, and the corresponding molecules 
as part of the same cluster (extended scaffold), because of the close similarity with Medicinal Chemists 
methods of classification.  
Furthermore, since preliminary SAR from HTS data was one of the prerequisites, a compound description 
and classification in accordance with SAR in agreement with the Medicinal Chemistry “common sense” was 
mandatory, in order to obtain not only hits, but rather chemical classes ready to be moved toward  the “Hit 
to Lead” phase.  
Importantly, we employed a scheme to structure the IDDN chemical library in an efficient manner for a 
preliminary SAR expansion after HTS and data analysis. Toward this aim, scaffold decompositions were 
used to implement the concept of sub- and super- scaffold. Accordingly, a sub-scaffold is part of the parent 
scaffold lacking at least one ring system, while a super-scaffold has at least one ring system more than the 
parent one (Figure 50) 
 
Figure 50. 
Given this definition, the minimum number of rings to be considered is two. Therefore the procedure 
implemented starts with the extraction of Decorated Scaffolds as defined previously from all the selected 
compounds (~1M), then all the possible fragments containing at least two rings are recursively generated 
from each molecular framework. For example, if a given compound contains 4 rings, it will produce 3 
fragments containing 2 rings each and 2 fragments containing 3 rings each. Of all these fragments, to avoid 
building unrealistic clusters, fragments non-existing within the collected structures are removed and only 
those really present in the scaffold pool. 
 
Figure 51. Cytoscape plot of the fragment decomposition of 5 Decorated Scaffolds according to Molecular Assemblies set of roles. 
Grey cycles indicates real scaffolds present in the dataset. All the upper 5 Decorated Scaffolds have one fragment in common that is 
itself a Decorated Scaffold. This pool of Decorated Scaffolds is defined as Extended Scaffold an all the molecules belonging to one of 
this Decorated Scaffolds are part of the same cluster (Figure 52). 
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It is important to underline that super-scaffold  - i.e. molecular frameworks with one ring more than the 
reference compound (centroid) for any given cluster - are not built by adding ring systems, but, more 
simply, by establishing relationships within existing compounds. Molecules having a scaffold that is a sub- 
or a super- scaffold of another molecule scaffold have been grouped together and the new group is called 
extended scaffold (Figure 52).  
 
 
Figure 52. Molecules (Green) having a scaffold belonging to the same extended scaffold 
Molecular Assemblies concept can also be very useful for establishing relations between different extended 
scaffolds (Figure 53). 
 
Figure 53. 
Other Molecular Assemblies representations can be used to support the analysis of the chemical space and 
in the SAR analysis. For example, selecting one Basic Wireframe is possible to visualize all the compounds 
having that MABW in common and the structural relations  connect all the molecules in the cluster (Figure 
54). 
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Figure 54. 
Finally using InChi Keys string pattern, matching the associations between initial molecular framework and 
sub-scaffolds sharing part of the so-called Super Scaffold are established and the cluster is therefore 
defined.  
The first analysis of the resulting clusters showed the presence of some overpopulated clusters (>1000 
members). We decided to reduce the maximum number to 150, by selecting the corresponding most 
diverse molecules using Tanimoto (8) metric based of ECFP_6 descriptors. 
To have an acceptable representation of different substitutions for molecules belonging to the same 
clusters in a collection designed to have 208K molecules we arbitrarily reputed that an average of 20 
molecules for each cluster (i.e. 1/10000 of the whole set) would be sensible. At the same time the 
maximum number for each cluster was limited to 50 members. These two values (AvgSize 20, MaxSize 50) 
are the result of an iterative process so that the maximum number of clusters (i.e. scaffolds) available 
within the molecule dataset is selected, while the total number of compounds does not exceed 208K. At 
the same time the lower limit for each cluster was set to 10 to allow the selection of one representative for 
each Diversity Set still leaving six molecules for the hit expansion. 
To choose 50 molecules out of – in some cases – 150 we again applied  the diversity method based on 
Tanimoto (8) distance metric using ECFP_6 descriptors as implemented in PipelinePilot (Accelrys). The 
desired number of the most diverse molecules was selected and five non-redundant subsets were formed. 
The first four   “Diverse” sets are made of representative members of each cluster obtained through the 
procedure described above. The first  Diverse set collects all the cluster centroids, i.e. the molecules with 
the minimal distance from each other member within the same cluster. This was done using ECFP_6, Jarvis-
Patrick algorithm and Tanimoto distance metric as implemented in Pipeline Pilot, resulting in 10000 
compounds. The second, third and fourth Diverse sets consist of three other centroids, which are defined 
as follows: a) for each cluster as defined above, up to the top 50 most diverse molecules are selected; b) 
each cluster is then divided in three sub-clusters of about same size, using diversity calculated above as 
ranking parameter; c) out of each sub-cluster the centroid is identified; d) each centroid is then numbered 
and assigned to its own sub-sets. In the end four sets are produced: Cluster Centroids (LibraryID1), Sub-sets 
1, 2 and 3 (LibraryID2, LibraryID3 and LibraryID4) of about 10000 compounds each for a total of 40000 
compounds. The remaining ~168K molecules went into the fifth set. All and each of the molecules 
belonging to this fifth set must have one representative in each of the four diversity sets. Relationships 
between molecules are kept using InChikeys and those not fulfilling this criteria are removed. 
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6.3 RESULTS AND DISCUSSION 
As briefly previously reported, the two main goals of this library construction were a) capability to derive a 
preliminary SAR from HTS data and b) assembly of the library so that the above goal is possible without 
performing cherry picking, i.e. selecting single compounds, but otherwise using complete plates as “scaffold 
collections”. To achieve these, some conditions were fulfilled. The first one is that each scaffold, or 
chemotype, should have enough representatives with typical substituent variations, but still maximizing 
diversity15,16. Then the classification should take care of relationships between similar scaffolds, in particular 
those connected by addition or removal of a ring system. Finally, similar compounds must be plated 
together, so that the ratio of interesting compounds versus the other plate members is as high as possible, 
once a scaffold has been found active after screening of the four diversity sets. Since the compounds came 
from six different vendors, the approach took in account this constraint as well, and, for obvious logistical 
reasons, compounds coming from different vendors are not intermixed, and there are no duplications 
between vendors. 
From the above requirements, we derived all the parameters we used in the library design. Given 208000 
compounds as the maximum number to be taken into account, in accordance with logistic and economical 
constraints, we decided that an average of 20 compounds for each cluster could produce a minimal SAR. At 
the same time this produces what is considered the minimal diversity set (~10000 cmpds), which is at the 
same time the number of clusters based on the scaffold metrics described above. Considering that these 
constraints could dramatically reduce chemical diversity, and keeping in mind the definition of Decorated 
Scaffold, where the scaffold is almost identical within the clusters, we decided to select at every step where 
it was required always the top diverse molecules, since the diversity would have been contained in the side 
chains and therefore would not disrupt the scaffold based clusterization. Furthermore we decided to 
replicate for a total of four times the process of centroids extraction for each cluster, to provide another 
degree of flexibility when performing HTS assays. This resulted in 4 diversity subsets, each of them 
containing about 10000 molecules, each of them representative of the whole library, and, when used all 
together, representing 20% of the whole library. 
This new definition was implemented because including molecules having a fragment scaffold of the super 
scaffold could simplify the identification of the part of the scaffold carrying the most relevant 
pharmacophore; in addition, introducing molecules having scaffolds that can create relations between 
different scaffolds having a partial overlap in the chemical structure allows a better understanding of the 
role of the scaffold and the effects of scaffold modifications in the biological activities helping in the 
identification of analogues and, eventually, for scaffold hopping activities. 
6.4 CONCLUSIONS 
In this work, we have demonstrate how is possible to implement Molecular Assemblies in the library design 
process in order to generate drug like, SAR-oriented, HTS ready chemical libraries. The definition of an 
extended scaffold, as an application of the fragmentation’s rules, overcome the limits of other scaffold 
metrics that are not able to cluster together molecules having only a partial overlap in the scaffold because 
of the intrinsic definition of scaffold (the rings and the chains connecting them). 
The use of the full MA descriptor, instead of extended scaffold, will guide the analysis of the results offering 
multiple interpretation of the SAR. Active molecules may have in common the scaffold, the framework of 
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the wireframe or even a fragment of them in any case MA descriptor will able to generate all possible 
relations between active molecules. 
The use of MA metrics for clustering enabled the efficient clustering of the entire chemical space. MA have 
no need to introduce bias such as the expected number of molecules per cluster, the expected number of 
clusters, the number of nearest neighbor, the definition of cluster centroid.  
As demonstrated in Chapter 5, cluster by MA is a simple function of the number of molecules, so it is 
possible to cluster the initial set of 1.1 million compounds in a few minutes. It is a remarkable result if 
compared to other clustering methods based on distances were clustering is a function of the number of 
molecules to the power or two or even three in the case of Jarvis-Patrick algorithm. 
The design and acquisition of this chemical library is a shining example of a successful attempt to explore 
novel R&D models. The Italian Drug Discovery Network, composed of pharmaceutical companies, public 
and private research institutions, as a small precompetitive joint initiative, has demonstrated that is 
possible to accelerate and promote  drug discovery. Providing, as a network, the human and financial 
resources to achieve the required critical mass to compete in this arena.  
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7 CONCLUDING REMARKS 
I have dedicated my PhD to the development and validation of new methodologies and software tools for 
research and development workflow. I have also been able to apply such tools to actual drug discovery 
projects to demonstrate that they were able to implement and support the very first step of R&D processes. 
In fact, hit finding and hit to lead development are the crucial steps for the fate of the projects, even 
though they are also the cheaper ones. The first identification of high quality hits,  that can be rapidly 
progressed to validated hit series and then optimized to obtain good preclinical leads, strongly bias the 
chance of success of the projects. In fact, an ineffective choice of the starting point will produce a failure in 
the subsequent and more costly phases.  
The two methodologies I identified are:   
 LiGen,  a molecular mechanics engine for structure-based virtual screening 
 Molecular Assembles,  a molecular descriptor for cheminformatics applications 
Even though they are very different from each other, they both find application in the same computational 
field. They could be used in an integrated way thus addressing the whole challenge of identifying valuable 
hits, instead of supporting vertically specific tasks one by one with standalone computational tools. 
In the specific case of this thesis, Molecular Assembles has been used in the design and assembly of the 
IDDN chemical library (chapter 6) that was subsequently tested through biologic functional assays. In these 
processes, Molecular assembles makes HTS data analysis easier by guiding the SAR analysis. Moreover, the 
use of well-designed libraries in structure based virtual screening allows the optimization of computational 
resources and human effort in the analysis of the results, since they are immediately focused on high 
quality drug-like molecules with a good balance between chemical diversity and the possibility to establish 
structure activities relationships.  
On  the other hand LiGen has proved able in supporting the de novo design of novel C5aR allosteric 
inhibitors. 
Such a combined approach greatly enhances the expected hit rate. Nevertheless, even more important 
than the hit rate is the possibility to analyze the results of small congeneric series (molecules having the 
same scaffold) by the means of the 3D interactions with the active site. This modus operandi allows the 
validation of the prediction power of the 3D model with the experimentally determined ligand based SARs 
directly in the first round of screening. 
The final goal of any HTS campaign is the identification of a small set (from 3 to 10) of validated hit series 
having the highest chances to progress up to a lead instead of tens of single active compounds. So the final 
goal of computational medical chemistry and more in general of the CADDD is to foster the integration of 
the in silico tools with the drug discovery and development workflow providing reliable predictions by using 
interpretable models to support the decision making process. 
Molecular Assembles and LiGen are ongoing projects, used in all our early drug discovery projects. Changes 
and optimizations are determined by the performance and the limitations in real world applications. For 
example, working on a project with very flexible ligands, we revealed the need for an implemented novel 
algorithm for the identification of the first pose of the ligand in the active site.  
The main enhancements already scheduled are: 
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 Molecular Assembles will be re-written in C++ (the actual implementation is in Java and requires 
Accelrys Pipeline Pilot API) using the part of the LiGen code devoted to the substructure search and 
reagent mapping. This implementation will also allow LiGen natively to take into account the 
scaffold metrics in the virtual screening. 
 LiGen scoring function will be re-implemented form scratch and in 2015 the optimization of the 
source code for the INTEL xeon phi accelerators will be completed. 
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